



HAL
open science

Cancer's second genome: Microbial cancer diagnostics and redefining clonal evolution as a multispecies process

Gregory Sepich-Poore, Caitlin Guccione, Lucie Laplane, Thomas Pradeu, Kit Curtius, Rob Knight

► **To cite this version:**

Gregory Sepich-Poore, Caitlin Guccione, Lucie Laplane, Thomas Pradeu, Kit Curtius, et al.. Cancer's second genome: Microbial cancer diagnostics and redefining clonal evolution as a multispecies process. *BioEssays*, 2022, 44 (5), pp.2100252. 10.1002/bies.202100252 . hal-03883528

HAL Id: hal-03883528

<https://hal.science/hal-03883528>

Submitted on 3 Dec 2022

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

1 **Solicited special issue:** "Advances in Cancer Diagnostics"

2 **Submission type:** Review essay

3 **Manuscript title:** Impact of the cancer metagenome on clinical care and multispecies clonal
4 evolution

5 **Authors & Affiliations:** Gregory D. Sepich-Poore^{1,†}, Caitlin Guccione^{2,3,4,†}, Lucie Laplane^{5,6,‡},
6 Thomas Pradeu^{7,‡}, Kit Curtius^{2,3}, Rob Knight^{1,4,8,*}

7 ¹Department of Bioengineering, University of California San Diego, La Jolla, CA 92093, USA.

8 ²Division of Biomedical Informatics, Department of Medicine, University of California San Diego,
9 La Jolla, CA 92093, USA.

10 ³Bioinformatics and Systems Biology Program, University of California San Diego, La Jolla, CA
11 92093, USA.

12 ⁴Department of Pediatrics, University of California San Diego, La Jolla, CA 92093, USA

13 ⁵Institut d'histoire et de philosophie des sciences et des techniques (UMR8590), CNRS &
14 Panthéon-Sorbonne University, 75006 Paris, France.

15 ⁶Hematopoietic stem cells and the development of myeloid malignancies (UMR1287), Gustave
16 Roussy Cancer Campus, 94800 Villejuif, France.

17 ⁷ImmunoConcept (UMR5164), CNRS & University of Bordeaux, 33076 Bordeaux Cedex,
18 France.

19 ⁸Department of Computer Science and Engineering, University of California San Diego, La Jolla,
20 CA 92093, USA.

21 [†]These authors contributed equally.

22 [‡]These authors contributed equally.

23 *Corresponding author: robknight@eng.ucsd.edu

24 **Keywords:** cancer microbiome, clonal evolution, diagnostics, therapeutic modulation,
25 prognostics

26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47

SUBTITLE

Humans and their tumors are not aseptic, and the multispecies nature of cancer modulates clinical care and clonal evolution.

ABSTRACT

The presence and role of microbes in human cancers has come full circle in the last century. Tumors are no longer considered aseptic, but implications for cancer biology and oncology remain underappreciated. Opportunities to identify and build translational diagnostics, prognostics, and therapeutics that exploit cancer’s second genome—the metagenome—are manifold, but require careful consideration of microbial experimental idiosyncrasies that are distinct from host-centric methods. Furthermore, the discoveries of intracellular and intra-metastatic cancer bacteria necessitate fundamental changes in describing clonal evolution and selection, reflecting bidirectional interactions with non-human residents. Reconsidering cancer clonality as a multispecies process similarly holds key implications for understanding metastasis and prognosing therapeutic resistance while providing rational guidance for the next generation of bacterial cancer therapies. Guided by the above opportunities and challenges, this Review describes opportunities to exploit cancer’s metagenome in oncology and proposes an evolutionary framework as a first step towards modeling multispecies cancer clonality.

48 **INTRODUCTION**

49

50 A long and rich history exists between microbes and cancer. As early as 1550 BCE, Egyptian
51 writings suggested a crude therapy for tumors through incision and application of a poultice,
52 thereby inciting an infection.^[1–3] Nearly three millennia later, Saint Peregrine Laziosi (c. 1265–
53 1345) documented spontaneous regression of a septic sarcoma on his leg large enough to pierce
54 through skin.^[2] Although these accounts predated modern germ theory, they presciently
55 associated acute infections and the retrogression of cancer, which would be independently re-
56 discovered by three physicians between 1868-1893: Wilhelm Busch, Friedrich Fehleisen, and
57 William Coley.^[4–6]

58

59 Many spontaneous tumor regressions described by these three physicians were tied to the skin
60 pathogen *Streptococcus pyogenes*, and its concomitant infectious syndrome, erysipelas.
61 However, only Coley seriously considered treating new patients—usually with late-stage or
62 inoperable cancers—by administering live bacteria (which carried serious clinical sequelae), and,
63 later, heat-killed microbial (*Streptococcus* and *Serratia*) toxins. These clinical experiments
64 revealed >10-year disease-free survival in 60 of 210 patients across multiple cancer types,
65 roughly one-third of all patients treated—a statistic only matched by modern immunotherapy.^[7]
66 Nonetheless, an unknown mechanism and severe flu-like side effects made ‘Coley’s toxins’
67 unpalatable to oncology, especially when compared to the burgeoning radiotherapy and
68 chemotherapy fields.^[8,9] It would take another century for scientists to realize that Coley’s
69 approach comprised the first intentional application of immunotherapy, and accurately predicted
70 a causal relationship between immunotherapy efficacy and an individual’s endogenous or
71 exogenously-administered microbiome.^[10–16]

72

73 Viruses have also been crucial for understanding cancer and its genetic material. Peyton Rous's
74 seminal 1911 discovery of his eponymous, transmissible, oncogenic, RNA virus galvanized
75 investigation of the viral origins of cancer, leading to key links between Epstein-Barr, human
76 papilloma (HPV), hepatitis, and most recently Merkel cell polyomavirus and carcinogenesis.^[17–19]
77 Although several decades of laborious research led to the conclusion that viruses cause only a
78 minority of cancers, the pursuit of oncogenic viruses indirectly led to the definition of and search
79 for 'oncogenes' capable of transforming benign tissue into malignant tissue.^[19] One particularly
80 important oncogene was *src*, a protein kinase identified in transforming-only strains of Rous's
81 Sarcoma Virus (RSV), but found by Michael Bishop and Harold Varmus to exist in cells of non-
82 infected, phylogenetically-divergent birds.^[20] Their data suggested a non-viral, cellular origin of
83 *src*: hosts normally contain oncogenes, and transforming strains of RSV had acquired one. This
84 discovery earned them the 1989 Nobel Prize in Medicine.^[19,20] Realizing oncogenes were *internal*
85 to cancer motivated characterization of all possible oncogenes in the human cancer genome by
86 sequencing the normal human genome as a reference.^[21] Modern cancer genomics thus had its
87 roots in tumor virology.

88
89 The story of RSV and its hijacking of *src* showed how genetic information could transfer between
90 tumors, microbes, and their hosts over evolutionary time and under various selection pressures.
91 After Rous's initial discovery, successive passaging of RSV enabled researchers to evolve the
92 chicken-specific virus to induce tumors in ducks and pigeons, then rats, rabbits, and mice,
93 presumably by activating similar kinase-related oncogenic pathways.^[19,22,23] This process
94 represented early examples of intentional transfection and directed evolution, whereby recipient
95 cells received potent genetic cargo capable of being expressed to change cellular fitness.
96 Decades later, a similar ability of bacteria to transfect genetic material, either microbial or human
97 in origin,^[24–28] to cells—including cancer cells^[29]—with subsequent protein expression would be

98 demonstrated and coined “bactofection.”^[30] Bactofection was primarily sought after as an
99 alternative to conventional gene therapy or vaccination, but has received little attention.^[27,30,31]

100

101 Since Bishop and Varmus’s discovery shifted attention to factors internal to the cancer cell, the
102 last 30 years of cancer research has primarily focused on characterizing all major coding,
103 noncoding, structural, and copy number aberrations in the cancer genome.^[32–36] Substantial study
104 of the tumor microenvironment (TME) has further elucidated the impacts of heterogeneous tumor
105 architecture, spatial organization, and multifaceted cellular agents (e.g., immune and stromal
106 cells) on cancer evolution, clonality, antitumor immunity, and metastasis.^[37–39] Further work has
107 revealed similarities between microbial and cancer evolution. For example, the ubiquitous
108 presence of plasmid-like, extrachromosomal DNA (ecDNA) segments and their unequal
109 segregation during cancer cell division is analogous to unequal segregation of high copy plasmids
110 during bacterial replication.^[40–44] Hybrid viral-human sequences on ecDNA segments in HPV-
111 infected cancers even contribute to immune evasion and carcinogenesis.^[45,46] Nonetheless, most
112 cancer ‘omic’ studies have portrayed tumors as sterile entities, and microbial constituents as
113 being unrelated to tumor evolution or clinical care.

114

115 The last five years have persuasively unveiled metabolically-active, immunoreactive, intracellular,
116 cancer type-specific communities of bacteria (and viruses) living within tumor tissues, several of
117 which modulate cancer therapies.^[47–60] These microbes may move during metastasis from one
118 bodily location to another and facilitate leaving and/or seeding of metastatic cancer cells.^{[53,54,61–}
119 ^{63]} Critically, intratumoral and gut microbes can create chemo-, radio-, and hormonal therapeutic
120 resistance without any genetic or non-genetic changes within the cancer genome.^[47,64,65]
121 Conversely, microbiota may render other chemo-, radio-, hormonal, and immunotherapies
122 possible and/or effective without any intervention from cancer cells.^[12–14,64,66–68] Trace amounts of
123 cancer type-specific bacterial DNA have also been identified in the circulation of cancer patients,

124 suggesting a novel class of microbial cancer diagnostics.^[58,69] Most, if not all, human cancers lack
125 sterility, and their microbes are clinically relevant.

126

127 Towards building a microbially-conscious framework of cancer, we posit cancer-bearing humans
128 as meta-organisms colonized by numerous and diverse microbial constituents (see **Box 1**—
129 “Quantifying the cancer microbiome”).^[70,71] We propose the clinical utility of microbial information
130 as cancer diagnostics, prognostics, and therapeutics and consider (intracellular) microbes as live,
131 mobile agents within tumors that encounter selection pressures alongside/within cancer cells.
132 Finally, we hypothesize that fundamental ecological rules governing microbial activity and spatial
133 placement (e.g., redox, chemotactic, oxygen gradients)^[72] outside tumors also govern them inside
134 tumors. This Review details the study of cancer’s “second genome” and its use to advance patient
135 care and models of cancer clonal evolution.

136

137

138

BOX 1—Quantifying the cancer microbiome

Broadly speaking, the human body microbiota include $\sim 4 \times 10^3$ species accounting for $\sim 4 \times 10^{13}$ total microorganisms, with $\sim 97\%$ of those cells comprising colonic bacteria and $\sim 2\text{-}3\%$ comprising extra-colonic bacteria while archaea and eukarya—including fungi—comprise smaller populations around $\sim 0.1\text{-}1\%$ of the total microbial abundance.^[70,73] Human virus and phage abundance estimates remain undercharacterized but likely have even greater diversity than bacteria.^[74] The human gut microbiome contains the largest bodily microbial biomass by far—roughly 0.2 kilograms^[70,75]—with substantial effects on host antitumor immunity.^[3] Biomass estimates of other body sites or tissues remain unknown.

Intratumoral microbiome diversity estimates with stringent decontamination controls ($\sim 1\text{:}2$

control to sample ratio) suggest that at least 500 distinct bacterial species inhabit tumors.^[57] Intratumoral microbiome abundance estimates have been inferred using shotgun read quantification and quantitative polymerase chain reaction (qPCR) of 16S rRNA.^[57,58] Microbial profiling of all whole genome and transcriptome studies from The Cancer Genome Atlas (TCGA) revealed an average of 2.5% of total sequencing reads to be microbial and an average of 0.9% of total reads that were resolvable at the genus-level.^[58] Given the difference between typical microbial and human genome sizes—often 10^3 -fold smaller—it is possible that these percentages underestimate true microbial density. To quantitate abundance, bootstrapping 16S rRNA qPCR data by Nejman *et al.* revealed a heterogeneous average number of bacteria per cancer type, ranging from ~13 to ~70 per 40 nanograms (ng) of DNA, among seven major human cancers (**Table 1**).^[57] The pan-cancer average was 34.19 bacteria per 40 ng of DNA (**Table 1**). To translate these values to percent tumor composition, it is necessary to first estimate the number of tumor cells per 40 ng of DNA. One way to estimate this for haploid cells is as follows:

$$\begin{aligned}
 \text{DNA mass (haploid)} &\approx (3.2 \times 10^9 \text{ bp/cell}) \left(\frac{1 \text{ mole}}{6.022 \times 10^{23} \text{ bp}} \right) \left(\frac{660 \text{ g}}{1 \text{ mole base pair}} \right) \\
 &\approx 3.5 \text{ picograms / haploid cell}
 \end{aligned}$$

To translate from haploid cell to tumor cell, an estimate of ploidy is needed, which can be derived from the most recent Pan-Cancer Analysis of Whole Genomes (PCAWG) dataset.^[32] The mean estimated ploidy in PCAWG across all human cancers is 2.36 and ranges from a low of 1.28 to a high of 6.22. If we assume average cancer ploidy, the average DNA mass per cancer cell is thus:

$$\begin{aligned} \text{DNA mass (cancer cell)} &\approx (3.5 \text{ picograms / haploid cell}) \times (2.36 \text{ avg. ploidy}) \\ &\approx \mathbf{8.26 \text{ pg / cancer cell}} \end{aligned}$$

Similarly, the range of DNA masses per cancer cell based on ploidy would be 4.48 pg to 21.77 pg. For simplicity, one can round the average mass value to 8 pg/cancer cell. Assuming that the DNA mass of microbes is negligible compared to that of the host, since its genome is roughly 10^3 -fold smaller and there are fewer of them expected, then the estimated percent composition is as follows:

$$\begin{aligned} \text{Pure tumor bacterial composition} &\approx \left(\frac{34.19 \text{ bacteria}}{40 \text{ ng DNA}} \right) \left(\frac{0.008 \text{ ng}}{1 \text{ cancer cell}} \right) (100\%) \\ &= 0.68\% \text{ bacterial} \end{aligned}$$

This estimate, however, assumes 100% tumor purity. Fortunately, PCAWG estimated tumor purity across the same samples, showing an average tumor purity of 63.8%.^[32] Instead of 5000 cancer cells per 40 ng of DNA, assuming 8 pg per cancer cell, average tumor purity suggests 3190 cancer cells with the remaining cells comprising the TME. While this does not change the percent bacterial composition of the tumor, it does change the ratio of bacteria to cancer cells to approximately ~1:100 or ~1% (i.e. 34.19 bacteria:3190 cancer cells; **Table 1**). Using the 95% confidence interval bounds of the pan-cancer mean number of bacteria per tumor (**Table 1**) gives a range of 0.75% to 1.46% bacterial.

In the case of high tumor ploidy and low tumor purity, it may become important to weigh the contributions between tumor (aneuploid) and stroma (diploid) to the number of cells within 40

ng of DNA. This may be done as follows, for example using a tumor ploidy of 6.0 and 20% purity:

$$\begin{aligned} \text{Composition} &\approx \left(\frac{34.19 \text{ bacteria}}{40 \text{ ng DNA}} \right) \left[\frac{20}{100} \left(\frac{0.02177 \text{ ng DNA}}{1 \text{ cancer cell}} \right) + \frac{80}{100} \left(\frac{0.007 \text{ ng DNA}}{1 \text{ stromal cell}} \right) \right] (100\%) \\ &= 0.85\% \text{ bacterial} \end{aligned}$$

whereas a tumor of 100% purity at a ploidy of 6.0 would provide an average tumor bacterial composition of 1.86%. It is noted that cases with high ploidy and high purity will maximize this percentage value, in addition to when there is more observed bacteria.

To compare these bacterial abundances to intratumor immune cell populations, which are usually reported as densities of immune cell counts per square millimeter, it is necessary to first estimate the total number of cells per square millimeter in a tumor. While a handful of density estimates exist in the literature, such as a mean of 5,558 cells (SD 1,980) per mm² in metastatic melanoma,^[76] it can be inferred directly from circle packing theory.^[77] Specifically, given the average diameter of cells in a tissue, then the number of possible cells within the 1 mm² square can be calculated. In one way, this can be interpreted as a conservative estimate since cells are often compressed and non-circular in real tissues; conversely, it may overestimate cell density in regions with dense blood or lymphatic vessels. The typical diameter of lymphocytes approximates 6-7 μm in diameter^[78] while the diameter of cancer cells vary by type and are approximately ~20 μm in diameter across many cancer cell lines.^[79] Using average cell diameters of 12 μm, 15 μm, and 18 μm, circle packing theory predicts the following total cell abundances per 1 mm²: 8213 cells, 5208 cells, and 3589 cells.

Then, using the previously calculated average pan-cancer tumor bacterial composition of 0.68% (assuming tumor homogeneity), the estimated number of bacteria inferred as the following: 56, 35, 24 bacteria/mm² (assuming 12 μm, 15 μm, and 18 μm average diameter cells, respectively). Notably, these bacterial abundance estimates are similar to the proportion of PD1⁺ cells identified in a recent pan-cancer imaging dataset (~22 PD1⁺ cells/mm²) and roughly one-tenth of CD8⁺ T-cell density (~385 cells/mm²).^[80] Overall, the values reflected in this analysis may vary from tumor to tumor, depending on the assumptions made above—tumor ploidy, purity, homogeneity—but the analysis provides a rough approximation and analogy of intratumor bacterial abundances to immune cell abundances.

To summarize, these calculations estimate an average pan-cancer bacterial composition of ~0.68% with two- and three-dimensional estimates of ~35 bacteria/mm² (assuming 5200 cells/mm²) and approximately 6×10⁵ to 6×10⁶ bacteria per palpable 1 cm³ tumor (assuming 10⁸-10⁹ cells/cm³).^[81] Notably, these estimates can vary between patients by three orders of magnitude and require further examination in additional cohorts.

139
140
141
142
143
144
145
146
147
148

TABLE 1. Abundance estimates of intratumoral bacteria among seven major human cancers profiled by Nejman *et al.* (data shared via private communication with Ravid Straussman).^[57] One thousand iteration-bootstraps of the mean approximated the average number of bacteria per 40 nanograms of DNA on a per-cancer and pan-cancer basis. Conversions and assumptions of tumor ploidy, purity, and homogeneity are detailed in **Box 1**. Area density estimates assume 5200 total cells/mm² and volume density estimates assume 10⁹ total cells/cm³.

Cancer type in Nejman <i>et</i>	qPCR sample size (<i>n</i>)	Absolute range (bacteria/40ng) (min, max)	Bootstrapped estimate of average bacteria per 40 ng	Area density estimate	Volume density estimate
---------------------------------	-------------------------------	---	---	-----------------------	-------------------------

<i>al. 2020</i> ^[57]			DNA (mean, 95% CI) (1000 iterations)	(bacteria /mm ²)	(bacteria/ cm ³)
Melanoma	200	(0.85, 3023)	31.69 (9.71, 71.20)	~33	~6.3×10 ⁶
Lung	274	(1.2, 3663)	22.50 (7.90, 50.35)	~23	~4.5×10 ⁶
Ovarian	57	(1.84, 73.2)	12.72 (10.25, 16.00)	~13	~2.5×10 ⁶
GBM	37	(3.41, 77.4)	15.55 (10.89, 20.85)	~16	~3.1×10 ⁶
Pancreatic	66	(3.82, 2147)	70.43 (26.19, 147.78)	~73	~14×10 ⁶
Bone	30	(1.62, 76.4)	19.33 (13.97, 25.51)	~20	~3.9×10 ⁶
Breast	352	(0.765, 1723)	44.63 (31.41, 59.83)	~46	~8.9×10 ⁶
Pan-cancer	1016	(0.765, 3663)	34.19 (24.04, 46.56)	~35	~6.8×10 ⁶

149
150
151
152
153
154

CANCER MICROBIOME DIAGNOSTICS AND PROGNOSTICS


155

156 The concept of “strength in numbers” applies to cancer diagnostics, especially for low-biomass
157 material. For instance, liquid biopsies in cancer rely on detecting minute quantities of analytes
158 (DNA, RNA, proteins, or modifications thereof) shed from the tumor to diagnose the presence
159 and/or type of cancer.^[82] The low-biomass, limited unique number, and limits of detection of these
160 analytes usually restricts utility of liquid biopsies to tumors on the scale of multiple cubic
161 centimeters, corresponding to later stage cancers.^[82,83] Critically, more analytes or modifications,
162 even if rare, increase the overall sensitivity of the test sigmoidally.^[84] Cristiano *et al.* demonstrated
163 this principle using Monte Carlo simulations of liquid biopsies, showing that a test examining DNA
164 modifications comprising ≤0.001% of total plasma material could still have near-perfect sensitivity
165 if at least 256 alterations were interrogated.^[84]

166

167 These conclusions from cancer genomics suggest that the inherent diversity of the intratumoral
168 microbiome (≥ 500 unique bacterial species)^[57] and the gut microbiome ($\sim 4 \times 10^3$ bacterial
169 species)^[73] provide strong rationale for creating microbiome-focused cancer diagnostics, even if
170 any individual microbe is rare or lowly abundant. Two alternative ways of phrasing this idea is that
171 (i) high microbial diversity provides “many shots on goal” for making a single diagnosis and (ii),
172 using machine learning syntax, interrogating the microbiome is analogous to employing an
173 ensemble of many weak learners that collectively provide strong prediction performance (i.e., the
174 conceptual basis of boosting). We further note that for diagnostic purposes detected microbes do
175 not need to be causally associated with carcinogenesis but only consistently correlated with
176 cancer presence, absence, and/or growth. These microbial-informed or augmented diagnostics
177 and prognostics hold much potential to improve clinical cancer care (**Figure 1**).

178



179

180 **FIGURE 1.** Illustration of opportunities to enhance clinical cancer diagnostics and prognostics

181 using the cancer microbiome. Relevant references are listed in the title of each quadrant.

182

183

184 **Pre-cancer and cancer microbiome diagnostics**

185

186 Pre-cancer diagnostics identify lesions that are likely to progress to cancer but otherwise do not

187 meet the criteria for malignant tissue, most commonly including cervical and colorectal cancer

188 (CRC) precursors. With a focus on the gut microbiota, metagenomic studies have identified

189 distinct fecal microbial compositions between colonic adenoma-bearing hosts and healthy

190 individuals, often but not always with increases in *Proteobacteria* abundance.^[85-88] Yachida *et al.*

191 further characterized shotgun metagenomic and metabolomic shifts in the guts of healthy

192 individuals, those with polypoid adenomas, and those with stage 0 to stage IV CRCs, revealing

193 distinct stage-wise microbial and metabolic compositions sufficient to build fecal stage-specific
194 classifiers.^[85] Other studies of the vaginal microbiome have revealed distinguishable microbial
195 compositions and functions between healthy patients, those with cervical intraepithelial neoplasia
196 or cervical cancer, and modifying effects of HPV or HIV status.^[89–91] In a longitudinal trial, Usyk *et*
197 *al.* found that women presenting for high-risk HPV infection with abundant vaginal *Lactobacillus*
198 were more likely to clear the infection by their second visit (average 1.5 years later); conversely,
199 those with abundant vaginal *Gardnerella* upon presentation were much more likely to show
200 disease progression by the second visit.^[89] These studies suggest the opportunity for minimally-
201 invasive, swab-based stool and vaginal microbiome diagnostics that detect precursor cancer
202 lesions and/or forecast risk of cancer conversion.

203

204 Pre-cancerous syndromes are also pertinent for microbiome diagnostics, such as genetically-
205 driven familial adenomatous polyposis (FAP), pre-leukaemic myeloproliferation (PMP), and
206 *BRCA1* status, for they augur subsequent carcinogenesis in ways not fully predicted by host
207 genomics. For example, PMP is highly associated with *Tet2* mutations, but only a fraction of
208 people with germline *Tet2* mutations develop PMP or bona fide myeloid malignancies.^[92]
209 Comparing gut microbiota from patients with and without FAP, Dejea *et al.* elucidated that FAP
210 encourages biofilm formation comprising genotoxic strains of *Escherichia coli* and *Bacteroides*
211 *fragilis* with greater expression of their colibactin and *B. fragilis* toxins, thereby increasing IL-17-
212 dependent inflammation, DNA damage, and faster cancer conversion.^[93] Meisel and colleagues
213 then demonstrated that microbial translocation from the gut to systemic circulation with resultant
214 IL-6 production mechanistically drives conversion from predisposing *Tet2* germline mutations to
215 PMP.^[94] Nené *et al.* also reported significant cervicovaginal microbiome changes—absence of
216 *Lactobacillus* spp.—among *BRCA1*-positive, non-cancer-carrying women that were shared
217 among women with ovarian cancer, suggesting that germline mutations can affect microbial
218 composition and may show continuity with subsequent cancer conversion.^[95] Collectively, these

219 studies argue that pre-cancerous syndromes indeed modify and interact with microbiota,
220 suggesting an opportunity to develop diagnostic tools tracking their presence, and interventions
221 that reduce cancer conversion rates.

222

223 For solid tumor and blood microbiome diagnostics, Nejman *et al.* and Poore *et al.* provide the
224 most comprehensive analyses to date, demonstrating cancer type-specific microbial signatures
225 among >30 cancer types, showing their diagnostic applicability to human plasma samples, and
226 providing evidence of intracellular microbial localization in tumors.^[57,58] Nejman and colleagues
227 combined imaging, cultivation, qPCR, and a multi-region 16S rRNA sequencing strategy to
228 thoroughly characterize intratumoral bacteria among breast, bone, pancreas, brain, ovarian, lung,
229 melanoma, and colon cancers. Inclusion of 811 experimental contamination controls (i.e., DNA
230 extraction controls, no-template PCR controls, paraffin controls) for 1010 tumor samples enabled
231 stringent decontamination that removed 94.5% of detected bacterial species, leaving 528
232 confident species-level calls. Poore and colleagues used an alternative approach by mining all
233 whole genome and transcriptome sequencing data in TCGA (n=18,116 samples) and using
234 shotgun metagenomic strategies to derive ~2000 genus-level calls.^[58] *In silico* decontamination
235 based on sample DNA or RNA concentrations^[96] removed up to 92.3% of microbial information,
236 but machine learning performance to distinguish between cancer types and tumor versus adjacent
237 normal tissue remained strong. Based on historical and epidemiological data associating
238 bacteremias with subsequent CRC diagnosis,^[69,97] they then tested whether blood-derived,
239 genus-level microbes in TCGA were capable of distinguishing CRC from other cancer types.
240 Finding this to be true, they next tested whether blood-derived microbiomes could discriminate
241 between ~20 other cancer types, as well as when restricting samples to early cancer stages
242 (stages 1-2) and tumors without any canonical mutations on two commercial cell-free tumor DNA
243 (ctDNA) panels. Application of the same approach to 100 plasma samples from three cancer
244 types (lung, prostate, melanoma) and 69 HIV-negative, non-cancer controls suggested that cell-

245 free microbial DNA (cf-mbDNA) was capable of distinguishing between healthy and cancer
246 patients and between cancer types.^[58] Although the origin of cf-mbDNA remains unknown, we
247 speculate based on the literature a multiplicity of sources including the oral, gut, and intratumoral
248 microbiomes.^[53,61,62,98,99] We also speculate that the strength of the cf-mbDNA test derives from
249 the quantity of microbial biomarkers assayed rather than the absolute amount of microbial DNA
250 present in plasma, as analogously shown in fragmentomic-based liquid biopsies.^[84] Both of these
251 studies lay the foundation for multiple cancer detection tests using the cancer microbiome.

252

253 **Prognostics and companion diagnostics**

254

255 The impact of gut and intratumoral microbiomes on local and systemic immune tone and host
256 metabolites makes them versatile prognostics and companion diagnostics.^[3] Higher alpha
257 diversity of intratumoral or gut microbiomes prognoses long-term survivors in pancreatic and
258 cervical cancers, as well as in patients undergoing hematopoietic stem cell transplantation for
259 cancer therapy.^[52,100,101] Additionally, colorectal cancer stages reflect successive microbial
260 changes in the fecal microbiome,^[85,88] and early versus late stage lung cancer can be
261 distinguished through lower airway microbiota compositions.^[51] Intratumoral microbiomes can
262 similarly distinguish stage I from stage IV tumors in multiple gastrointestinal cancers (stomach,
263 colon, rectal) and renal cell cancer.^[58]

264

265 Therapeutically, numerous studies demonstrate how the efficacies of anti-CTLA-4 and anti-PD-
266 (L)1 immune checkpoint blockade (ICB) are predicted by and mechanistically tied to gut
267 microbiome composition and function,^[12–14,67,102–106] and recently the intratumoral microbiome has
268 shown a similar capacity.^[49,57] Similarly, the efficacy and host toxicity of cyclophosphamide,^[66,107]
269 gemcitabine^[47], and platinum-based^[67,108] chemotherapy depend on the composition and
270 metabolic capacity of gut and intratumoral microbiota.^[109] In specific cases, bacterial enzymes

271 directly degrade chemotherapy compounds into non-functional byproducts (e.g., gemcitabine
272 degradation by cytidine deaminase),^[47] suggesting colonized patients would have no drug
273 response or quickly develop therapeutic resistance. In HER2-positive breast cancer, antibiotic
274 administration impairs trastuzumab efficacy and fecal microbiota transplant from non-responders
275 to responders improves outcomes, implicating gut microbiota as critical agents for therapeutic
276 response.^[68]

277
278 Gut microbiota also affect hormonal therapies. Administration of abiraterone acetate (AA) in the
279 setting of castrate-resistant prostate cancer promoted outgrowth of *Akkermansia muciniphila* and
280 appeared to aid overall AA therapeutic efficacy.^[110] However, androgen deprivation therapy also
281 increases gut-residing *Ruminococcus* species containing CYP17A1-like enzymes that catalyze
282 pregnenolone conversion to the sex hormone precursor dehydroepiandrosterone (DHEA) and
283 testosterone, thereby enhancing progression to castration-resistant prostate cancer.^[65] Thus,
284 targeted longitudinal profiling of implicated gut microbes may provide an early indicator of failing
285 androgen deprivation therapy while also substantiating their timed targeted removal. It has been
286 speculated, albeit unproven, that estrogen-receptor-positive breast cancer may similarly be
287 affected by microbial hormone metabolism.^[111,112] It further remains unknown if or how
288 intratumoral microbes affect hormonal metabolism. Altogether, the myriad of gut and intratumoral
289 microbiome effects on virtually every domain of cancer therapy and predictive associations with
290 patient survival enforce their clinical utility as prognostic indicators and companion diagnostics.

291

292 **Challenges for cancer microbiome diagnostics and prognostics**

293

294 Low-biomass microbial sampling creates analysis challenges that necessitate careful
295 consideration and removal of contamination.^[113,114] While less impactful in gut microbiome studies
296 or large-scale meta-analyses, external (e.g., environmental) and internal (e.g., cross-seeding


297 between samples) contamination can skew small-to-moderate scale profiling of the cancer
298 microbiome.^[113,114] Standardized experimental contamination controls (**Figure 2**) alongside *in*
299 *silico* decontamination methods^[96,114] can enable more robust and reproducible results, especially
300 for assaying intratumoral and blood-borne microbes, thereby enabling better microbiome-
301 augmented cancer diagnostics and prognostics. Notably, very few cancer genomics studies
302 implement any of these contamination controls and basic usage thereof would allow broad
303 utilization of “cancer-specific” data for simultaneous interrogation of microbial analytes, although
304 this may be overcome by integrating many thousands of samples.

305

306 Other challenges with microbiome studies include (i) the degree to which results vary with sample
307 and bioinformatics processing choices,^[115] (ii) fundamental differences in data properties and
308 appropriate statistics when using relative abundances compared to host ‘omic data,^[116–118] and
309 (iii) compositional differences as a function of geography and ethnicity, particularly when assaying
310 gut microbiota.^[119–121] One or more of these factors have, for example, resulted in three major
311 microbiome studies^[12–14] concluding that different gut microbes predict anti-PD(L)1
312 immunotherapy response—a fact that has remained irreconcilable despite analyses that
313 reprocessed all the data equally or instead examined their microbial functions.^[104] Large meta-
314 analyses can surmount some of these problems, with two key studies identifying conserved gut
315 microbial signatures predictive of colorectal cancer across diverse cohorts and
316 geographies.^[122,123]

317

318



319

320 **FIGURE 2.** Extracting and analyzing low-biomass microbiomes requires special care to control321 external and internal contamination.^[96,113,114] **(A)** Collection of environmental controls ideally322 begins in the operating room to account for non-patient environmental sources. **(B)** Post-operative

323 tissues, if paraffin embedded, can have non-tissue paraffin controls taken to ensure the

324 embedding process is not contaminated. Whole blood should ideally be collected with a skin swab

325 to account for peri-needle contamination. **(C)** Negative reagent-only 'blank' controls and positive

326 titrated controls should be processed simultaneously alongside nucleic acid extraction from

327 biological and environmental samples. **(D)** Plating strategies should be considered to reduce328 cross-contamination; controls may include up to 40% of total samples. **(E)** Amplification steps

329 may include PCR no-template controls and sequencing may include correction for cross-

330 contamination or index swapping, although the latter remains challenging.

331

332

333 REDEFINING CANCER CLONALITY AS MULTISPECIES

334

335 Redefining traditional meaning of clonal evolution and selection in cancer

336


337 Cancer cells evolve through space and time. Although the traditional view of clonal evolution has
338 historically centered on genetic alterations,^[37,124,125] it is increasingly recognized that non-genetic
339 alterations such as epimutations also contribute.^[126–128] The emergence of single-cell multi-omics
340 and longitudinal studies offers opportunities for a more inclusive, multi-analyte view of intratumor
341 heterogeneity and clonal evolution.^[129,130] Recognition of the role of multi-omics in functional clonal
342 diversity advocates for broader definitions beyond cancer genomics.^[38]

343


344 Research demonstrating effects of extracellular and intracellular microbes on the cancer cell
345 genome,^[93,131] transcriptome,^[48,50,51,132] proteome,^[49] and metabolome^[47,65] strongly justify their
346 inclusion in any multi-omic model of clonal evolution (**Figure 3**). Additional microbial functions
347 that enable or abolish chemo-, radio-, and/or immunotherapy efficacy without *any* interventional
348 cancer genomic changes provide further rationale for their inclusion.^[3,11,133] Intracellular
349 localization of metabolically active, immunogenic cancer microbes that shape cancer
350 immunoediting—evolutionary processes and selection pressures previously privileged to cancer
351 clonal selection—also provides justification.^[49,57,63] Identification of hybrid microbial-human reads
352 involved in carcinogenesis on plasmid-like ecDNA segments intimately links cancer and microbial
353 fitness.^[45,46] Microbial mechanisms that modify immunosurveillance also impact when and where
354 tumors grow and/or metastasize.^[49,53,54,61,62,134] Negatively, ignorance of microbial information in
355 clonal evolution precludes accurate identification of cancer dynamics, therapeutic resistance, and
356 metastasis. However, as distinct agents from cancer cells with separate genetic material that is,
357 at times, under discordant selection pressure(s) from the cancer genome (e.g., antibiotic therapy
358 for bacteria, targeted kinase therapies for cancer cells), there must be nuance. Cancer microbes

359 cannot merely be added as another “-ome.” Simultaneously, studies examining the roles of cancer
360 microbiota have not seriously considered the clonality of these microbes or their impacts on
361 cancer cell clonality. Thus, there is a persisting theoretical gap between the microbiota in cancer
362 and clonal evolution modelling that we propose bridging.

363



Multispecies clonal evolution



365 **FIGURE 3.** Impacts of intratumoral microbes on cancer evolution and arguments for multispecies
366 clonal evolution modelling. Effects are summarized into three major categories: modulation
367 ecosystem effects, mechanisms of clonal diversity, and example disjoint and joint phylogenetic
368 clonal evolution.

369

370

371

372

373 **Key evidence that argues cancer clonality is multispecies**

374

375 ***Decoupling of therapeutic efficacy from host and cancer cell genetic changes***

376

377 The genetic model of clonal evolution provides explanations for relapses caused by mutagenesis.
378 For example, mutations in cancer cell epidermal growth factor receptor (EGFR) induce resistance
379 to various generations of EGFR tyrosine kinase inhibitors while simultaneously creating favorable
380 selection pressures for mutated cells over non-mutated counterparts.^[135,136] As a result, EGFR-
381 mutated cells outcompete their neighbors and clonally expand.

382

383 However, this model fails to always explain treatment efficacy or failure, both for conventional
384 cancer and microbial-modulated therapies. For example, isocitrate dehydrogenase (IDH1/IDH2)-
385 mutated acute myeloid leukemia patients treated with IDH1/2 inhibitors can show complete and
386 sustainable responses to treatment without eliminating mutated cells.^[137–139] The same is
387 observed in chronic myelomonocytic leukemia treated with hypomethylating agents. Patient
388 responses, even when complete, demonstrate no decrease in the mutational load and no specific
389 selection events explaining secondary escape.^[140] Moreover, despite a clear reduction in cancer
390 cell burden, thereby generating a selective bottleneck, relapse can occur without genetic

391 selection. For example, in childhood B-cell precursor acute lymphoblastic leukemia, a recent
392 study by Turati *et al.* demonstrated how treatment with vincristine and dexamethasone drastically
393 reduced the leukemic burden but induced very little change, if any, in clonal composition.^[141]
394 Conversely, a transcriptional bottleneck was observed in single-cell RNA-Seq, with a major loss
395 in transcriptomic intratumor heterogeneity. A similar resistant transcriptomic profile was found in
396 the leukemic cells before treatment, suggesting positive selection of these rare pre-existing
397 resistant cells rather than induction of that phenotype under treatment exposure. These resistant
398 cells comprised a subfraction of low cycling cells and have been associated with a distinct
399 metabolic program.^[141,142] Several hypotheses are currently discussed with regard to this non-
400 genetic resistance to therapies,^[143] which mostly focus on transcriptomic and epigenetic
401 properties.

402

403 Classic genetic clonal evolution also fails to account for microbial-mediated treatment efficacy or
404 failure of (i) cyclophosphamide,^[66,107] gemcitabine^[47], and platinum-based^[67,108] chemotherapy; (ii)
405 anti-CTLA-4 and anti-PD-(L)1 ICB efficacy;^[12–14,102–106] (iii) androgen deprivation therapy in
406 prostate cancer,^[65] and (iv) trastuzumab in HER-2-positive breast cancer.^[68] Notably, some of
407 these examples (e.g., gemcitabine resistance) rely on *microbial* genetic content (e.g., cytidine
408 deaminase long (CDD_L) isoforms),^[47] which further may be shared among multiple species
409 through conventional horizontal gene transfer and may also be intracellular. Similarly, cancer
410 clonal selection may entirely occur on CDD_L-containing microbes by providing growth advantages
411 to those that can metabolize it as a concentrated carbon source, and cancer cell survival is tied
412 to CDD_L⁺-microbe proximity. Yet, cancer genome-centric evolutionary models miss all of these
413 effects and fail to accurately forecast evolutionary changes.

414

415 ***Impact of intracellular bacteria on cancer cell properties and fitness***

416

417 Immunohistochemistry, immunofluorescence, and electron microscopy data document the
418 intracellular localization of intratumoral bacteria.^[49,57,61,63] Bacteria inside cancer cells modify their
419 properties—transcriptional state,^[63] proteome,^[49] and metabolic repertoire^[47,57]—in ways that are
420 intrinsically tied to clonal evolution. Extracellular bacteria also modulate these properties and
421 cause cancer cell genomic mutations.^[93,131,144] Key affected clonal aspects comprise cancer cell
422 metabolism, immunoediting, clonal expansion and metastasis, and mutagenesis.

423

424 First, intracellular microbes change host cell metabolism, including degradation of exogenous
425 chemotherapy^[47] and xenobiotic D-alanine.^[57] Geller *et al.* originally identified microbial
426 gemcitabine resistance through incidentally discovering *Mycoplasma* contamination of cell
427 cultures and concomitant drug resistance.^[47] Isolation of the responsible enzyme and its drug-
428 degrading isoform (CDDL) followed by bioinformatic searches revealed >300 CDDL⁺ species,
429 98.4% within *Gammaproteobacteria*. Imaging, sequencing, and cultivation from gemcitabine-
430 associated pancreatic cancer patient biopsies indeed revealed CDDL⁺ bacteria in most samples
431 that conferred gemcitabine resistance in subsequent co-cultures with cancer cell lines.^[47]

432

433 Second, intratumoral microbes modulate the immune response, favoring immune escape, or,
434 conversely, recognition. *Fusobacterium nucleatum* inhibits natural killer cell (NK)-dependent
435 tumor killing through Fap2 interaction with TIGIT, constituting a bacterium-dependent mechanism
436 of tumor-immune evasion.^[145] Pancreatic cancer bacteria also induce innate and adaptive immune
437 suppression, including via selective Toll-like receptor ligation leading to T-cell anergy.^[48] Another
438 metastatic melanoma study elucidated immunogenic, MHC I and II-bound bacterial peptides
439 presented on cancer and immune cells that putatively shape cancer immunoediting and posit gut-
440 tumor antigenic overlap.^[49] Moreover, an uneven partitioning of microbes among cancer cells can
441 result in the differential elimination or maintenance thereof. Such a perspective enriches the

442 traditional “3Es” of elimination, equilibrium, and escape^[146] and documents how cancer cell fitness
443 is decoupled from its own genome.

444

445 Third, intratumoral microbes can favor cancer cell expansion and metastases. Bullman *et al.*
446 demonstrated *Fusobacterium* persistence in colorectal cancers through successive mouse
447 xenografts and similar bacterial compositions in matched primary-metastasis (colorectal-liver)
448 patient samples.^[61] Metronidazole treatment reduced tumor growth, implying greater fitness
449 conferred by *Fusobacterium* colonization.^[61] Bertocchi *et al.* later showed that colorectal bacteria
450 stepwise enter tumor tissue, modify the gut vascular barrier, migrate to the liver, and foster the
451 formation of a premetastatic niche favoring metachronous metastasis.^[62] Parhi *et al.* noted how
452 *Fusobacterium*-seeded breast cancers metastasized earlier. Hence, intratumoral bacteria
453 enhance metastatic formation and seeding.

454

455 Fourth, microbes cause genotoxin-mediated mutagenesis.^[93,131] Pleguezuelos-Manzano *et al.*
456 showed how *pks*⁺ *E. coli* generates mutational signatures in head and neck, colorectal, and
457 urinary tract cancers. Moreover, various gut-residing *Proteobacteria* species produce cytolethal
458 distending toxin (CDT) capable of inducing single- and double-stranded DNA breaks.^[144]
459 Collectively, all of these mechanisms shape cancer cell properties and fitness.

460

461 **Implications and hypotheses if cancer clonality is multispecies**

462

463 Imaging data portray intracellular bacteria as unevenly distributed among cancer cells and tumor
464 regions,^[57,61] suggesting differential fitness at the single cell level that may not correspond with
465 mutational status. This challenges the definition of cancer clones as private lineages of mutated
466 cells stemming from common ancestors and violates modelling assumptions whereby clonal
467 lineages comprise homogeneous cell populations. Although no two cancer cells are equal in every

468 respect, the primary assertion of clonality is that individual differences between two cancer cells
469 of the same clone are negligible.^[147] However, if intracellular bacteria alter phenotypes, behaviors,
470 and fitness of spatially-adjacent cancer cells, then they create major intraclonal heterogeneity,
471 which we define as “microbial intraclonal diversity” (MIDS). MIDS questions clonal lineage
472 homogeneity and motivates revising clonal boundaries, most simplistically through further
473 subsetting (e.g., *KRAS*-mutated, *Fusobacterium*-infected cells versus *KRAS*-mutated uninfected
474 cells) or more accurately through revised modelling approaches that account for discordant
475 microbe-cancer selection pressures. MIDS also includes mimicry between microbial and cancer
476 antigens.^[148,149] Should genetic cargo be shared between intracellular bacteria and host cells, as
477 biotechnology already shows is possible^[24] and cancer virology affirms,^[45,46] MIDS must account
478 for DNA and RNA from multiple species.

479

480 Beyond challenging clonal boundaries, intracellular bacteria may require revision of the
481 evolutionary tree. Typical clonal evolution model depicts an evolutionary tree with one trunk and
482 several branches, relying on the assumption of vertically transmitted traits from mother cells to
483 daughter cells at each round of cell division. If future research affirms horizontal/lateral gene
484 transfers between intracellular bacteria and host cancer cells, multiple tree trunks and connexions
485 between branches would be required. A similar debate has taken place in evolutionary biology,
486 challenging the traditional Darwinian view about “tree of life.”^[150–152] Clonal evolution may then be
487 better articulated as a case of “reticulated evolution,” wherein horizontal/lateral transfers change
488 the fitness, function, or/or phenotype of host cancer cells.

489

490 ***Considerations for cancer microbiome therapeutics under multispecies clonality***

491

492 Multispecies cancer clonality offers new therapeutic strategies that neither human nor microbial
493 clonality alone propose. For instance, Byndloss *et al.* demonstrated an interplay between

494 fastidious anaerobic gut bacteria and butyrate-mediated, PPAR- γ -dependent host signaling that
495 maintained low oxygen levels in the gut and prevented outgrowth of facultative pathogens.^[153]
496 Conversely, antibiotics increased gut oxygen concentration and pathogen outgrowth.^[153]
497 Analogously, there may be opportunities in cancer to target host processes that facilitate microbial
498 homeostasis as a means to mitigate microbial-mediated carcinogenesis in favor of blunted
499 antibiotics. Butler *et al.* provide another example whereby administration of a bacterial protease
500 depleted cellular MYC in colon and bladder cancers.^[154] Similarly, identification of anticancer
501 microbial enzymes or metabolites may provide effective host-modulating cancer therapies or
502 improve the efficacy of existing therapies—a strategy that several groups have already taken with
503 immunotherapy.^[105,106]

504

505 **EVOLUTIONARY MODELING OF THE CANCER MICROBIOME**

506

507 **Example of *Helicobacter pylori***

508

509 Incorporating intratumoral microbes into evolutionary models requires nuance because selection
510 pressures may be discordant with those experienced by cancer cells. A long-standing and well-
511 studied example of microbes in the cancer environment is *Helicobacter pylori*,^[155] which has
512 adapted to thrive in more than half of the human population long enough to trace human migration
513 events.^[156] *H. pylori* has co-evolved protective and pathogenic roles within humans: protective in
514 gastric cardia and esophageal adenocarcinoma^[157,158] and pathogenic in noncardiac gastric
515 cancer.^[155] Most *H. pylori*-positive patients carry multiple strains, including at least one strain
516 unique to their body along with more common strains such as VacA, CagA, and BabA.^[156] This
517 extreme genetic diversity stems from slipped-strand mispairing in multiple genes and *H. pylori*'s
518 lack of DNA repair genes unlike most bacteria.^[156] High strain diversity across individual human
519 hosts also enhances *H. pylori*'s population-wide resilience, allowing it to adapt to many diverse

520 environments by expanding upon the strain with the highest fitness in that setting. Collectively,
521 high diversity and concomitant mutagenesis of *H. pylori* combined with human immune selection
522 pressures and pathological impacts on noncardiac gastric carcinogenesis help portray an
523 exemplary “big picture” of multispecies cancer evolution. Building on this idea, we describe how
524 existing clonal evolution modeling may take intratumoral microbes into account.

525

526 **Common constraints of the tumor microenvironment**

527

528 As detailed above, the TME contains intracellular and extracellular microbes that affect cancer
529 clonality and comprise independent clonal agents. Importantly, the TME contexture applies
530 simultaneous, shared selective pressures and environmental constraints on co-located cancer
531 cells and microbes. Shared resources necessitate cooperative use and/or competition, which may
532 further limit their abundance. For instance, oxygen availability drives spatial organization and
533 metabolic capacities of cancer cells^[159] and is known to similarly affect microbes in environmental
534 contexts and model systems (e.g., Winogradsky columns).^[160–162] Common selection pressures
535 may in turn drive common evolutionary solutions, such as metabolic symbiosis between cancer
536 cells^[163] or between microbes positioned along the oxygen gradient.^[162] Gradients of pH are tied
537 to oxygen and common in tumors,^[159] and they shape microbial compositions in environmental
538 contexts.^[164] Hence, multispecies evolutionary models should take into account joint
539 environmental constraints.

540

541 Anderson and colleagues have presented compatible multiscale mathematical models of cancer
542 growth that take into account both cellular biophysical properties and TME factors.^[165–167] Their
543 model determined that aggressive cancer clones were established under the harshest TME
544 conditions (e.g., hypoxia, heterogenous extracellular matrix) but that their impact on overall tumor
545 invasiveness was blunted under milder TME conditions. Hence, microenvironmentally harsh

546 chemotherapy may worsen long-term cancer invasiveness. Incorporating microbes into their
547 multiscale model equations—their reliance and impact on TME chemical gradients and cancer
548 metabolism—could inform multispecies clonal dynamics and ideal TME conditions that in turn
549 would inform multispecies therapeutic strategies.

550

551 **Microbes affect clonal fitness**

552

553 As detailed above, intratumoral microbes affect cancer cell fitness, justifying their inclusion to
554 accurately model clonal evolution. Current models typically account for factors like probabilities
555 of cell division and cell death alongside inferred mutation rates and human driver genes. However,
556 intracellular microbes likely need to be included in these equations as well in certain scenarios,
557 particularly their mutational, division, and death rates. In circumstances of microbial enzymatic
558 degradation, such as CDD_L-mediated gemcitabine metabolism,^[47] transcriptional rates and
559 enzymatic efficiencies may be useful variables to include. In circumstances of genotoxin-mediated
560 mutagenesis, such as from *pks*⁺ *E. coli*,^[131] the base-pair motif and rate of mutations may also be
561 instructive to include.

562

563 Likelihood of clone development, treatment resistance, and fitness are all major parts of clonal
564 evolution models and are related to extracellular and intracellular microbes, but these have not
565 been typically considered in models of cancer evolution thus far. In common population genetics
566 models of clonal evolution, including Wright-Fisher diffusion type models^[168] and Moran type
567 models,^[169] it may be helpful to consider clonal fitness as a function of time-dependent fluctuations
568 in microbial abundances or presence/absence of particular species. Additionally, branching
569 process stochastic models of tumor growth that parameterize evolution in terms of proliferation
570 and mutation rates^[170–172] may also benefit from considering microbial colonization rates and
571 species-specific transcriptional effects. Furthermore, cancer microbes individually (and likely

572 jointly) undergo somatic clonal evolution, as described in the case of *H. pylori*. Phylogenetic tree
573 reconstructions of clonal evolution^[173] may thus need to include multispecies lineages, but
574 specialized methods likely need to be created for this purpose. To summarize, we have created
575 a table of major clonal evolution models and suggested strategies for incorporating microbial
576 information into them (**Table 2**).

577

578 **CONCLUSIONS**

579

580 Rigorous studies provide extensive evidence for the existence and functionality of cancer-
581 associated gut and intratumoral microbes while echoing ancient historical narratives of microbial-
582 mediated recovery. Drawing from cancer genomics, the inherently high diversity of the cancer
583 microbiome substantiates its strong predictive power, even when any individual microbe is rare
584 or lowly abundant. Cancer microbiota can distinguish healthy, pre-cancer, and cancerous tissues
585 across multiple cancer and sample types, although most diagnostics remain unvalidated in large,
586 multi-national, prospective cohorts. Cancer microbiota also demonstrate stage-specific
587 differences that may enable simultaneous identification and prognostication of tumors.
588 Nonetheless, contamination challenges in low-biomass settings and analytic idiosyncrasies of
589 microbiomic data have hitherto complicated routine clinical application of cancer microbial
590 diagnostics or prognostics.

591

592 Numerous microbial mechanisms affect the cancer genome, transcriptome, proteome, and
593 metabolome, advocating for their inclusion in models of cancer evolution. Extracellular and
594 intracellular microbes affect virtually every cancer medication class and may drive therapeutic
595 efficacy or resistance without any cancer cell(s) interventions. Negatively, it is not possible to
596 accurately model cancer-drug dynamics, clonality, or fitness without accounting for microbes.
597 Serious consideration of multispecies clonality, however, is complex and necessitates reworking

598 cancer evolution models since microbes carry distinct, although plausibly shareable, genetic
 599 cargo that may undergo discordant selection pressures from the cancer genome. Flexible
 600 evolutionary models treating intratumoral microbes as independent, albeit rule-abiding agents
 601 within the TME may be appropriate. Multispecies clonality also informs treatments, such that
 602 intentional modifications of cancer pathways may comprise more effective ways to restore healthy
 603 microbial ecologies than targeted antimicrobials, and vice versa. Multispecies treatment
 604 strategies may further benefit from target selectivity, for targeting microbial genes generally
 605 carries fewer side effects than targeting the host's. Altogether, understanding cancer's
 606 metagenome carries key ramifications for cancer care and clonal evolution for the benefit of
 607 patients worldwide.

608

609

610 **TABLE 2. Microbial integration into mathematical models of evolution.** Overview of each
 611 model's characteristics and references provided with modeling examples, as well as suggested
 612 ways that microbes could be potentially incorporated into model structure. Hybrid models that
 613 include aspects of more than one model type are also utilized in practice.

614

Model Type	Overview of Model	Examples of Potential Incorporation of Microbes	Literature
Agent-based model	<ul style="list-style-type: none"> ● Define 'agents' : individuals or members of the microenvironment with specific properties and actions on a structured grid or 3-D space ● Can have stochastic and deterministic components with spatial constraints ● Define environmental rules and presence of factors in space such as signalling proteins like VEGF ● Define agent-agent interaction rules 	<ul style="list-style-type: none"> ● Create microbe as one agent type and cancer cell as another agent type ● Allow clonal evolution of cancer cells and separate evolution of microbes in equations ● Create biophysical rules accounting for spatial movement of microbes and effect of microbes on evolutionary rates such as proliferation and survival of cancer cells ● Introduce complexity with microbes as agents within the 	[174,175]

		microenvironment	
Wright-Fisher type model	<ul style="list-style-type: none"> Population size remains constant over time (can be extended to growing populations) Considers finite number of population species/k-alleles To create the next non-overlapping generation, alleles are randomly sampled with replacement Allele frequency in new generation is combination of random sampling of population and the fitness of alleles Captures genetic drift and natural selection if included 	<ul style="list-style-type: none"> Microbes will likely not be directly considered in the population species, but instead the effects of microbes will be interwoven into fitness Fitness parameter of certain genotypes may depend on metabolites, proteins, and antigens from intracellular bacteria, which in certain cases may drive differential immunoediting between cancer cell-bearing bacteria 	[168,176]
Moran-type model	<ul style="list-style-type: none"> Two or more species considered in a population Asexual reproduction, overlapping generations Simultaneous birth and death events occur As in the Wright-Fisher model, can be formulated as a diffusion approximation 	<ul style="list-style-type: none"> Similar to the Wright-Fisher type model, microbes will likely not be directly considered in the population species, but instead the effects of microbes will be interwoven into fitness Fitness parameter of certain genotypes may depend on metabolites, proteins, and antigens from intracellular bacteria, which in certain cases may drive differential immunoediting between cancer cell-bearing bacteria 	[169,177]
Birth-death stochastic process	<ul style="list-style-type: none"> Continuous time Markov model (branching process) where 'birth' or 'death' events can change the state/population size A 'birth' increases the state by one A 'death' decreases the state by one Allows for multiple cell types (e.g., with/without driver mutations), fluctuations in total population size, stochastic extinction of cells, and mutation to other types 	<ul style="list-style-type: none"> Option 1 <ul style="list-style-type: none"> Birth and death defined in terms of human cancer cells with: <ul style="list-style-type: none"> Probability of birth and/or death affected by microenvironment Probability of birth and/or death dependent on a function of the population of intratumoral microbes present Option 2 	[178,179]

		<ul style="list-style-type: none"> ○ Birth and death events defined in terms of both human cancer cells and microbial populations 	
Evolutionary game theory model	<ul style="list-style-type: none"> ● Includes density-dependent fitness with cell-cell interactions ● Models cooperation, e.g., between tumor and stromal cells ● Fitness landscapes in non-cancer models have been central to understanding microbial evolution such as <i>E. coli</i> 	<ul style="list-style-type: none"> ● Include microbes as a type of “player” in the modeled ecosystem including tumor cells for limited chemicals and nutrients (e.g., oxygen, sugars, etc.) ● “Public good” produced by tumor cells, such as glycolytic acid and vascular endothelial growth factor, included in a game as competing resources with microbial populations 	[180–183]

615
616
617
618

REFERENCES

- 619 1. Ebbell, B. (1937). *The Papyrus Ebers: the greatest Egyptian medical document*. Levin &
620 Munksgaard.
- 621 2. Hopton Cann, S. A., van Netten, J. P., & van Netten, C. (2003). Dr William Coley and tumour
622 regression: a place in history or in the future. *Postgraduate Medical Journal*, 79(938), 672–
623 680. <https://www.ncbi.nlm.nih.gov/pubmed/14707241>
- 624 3. Sepich-Poore, G. D., Zitvogel, L., Straussman, R., Hasty, J., Wargo, J. A., & Knight, R.
625 (2021). The microbiome and human cancer. *Science*, 371(6536).
626 <https://doi.org/10.1126/science.abc4552>
- 627 4. Busch, W. (1868). Aus der Sitzung der medicinischen Section vom 13 November 1867. *Berl*
628 *Klin Wochenschr*, 5, 137.
- 629 5. Fehleisen, F. (1882). Ueber die Züchtung der Erysipelkokken auf künstlichem Nährboden und
630 ihre Übertragbarkeit auf den Menschen. *Deutsche Medizinische Wochenschrift*, 8(31),
631 553–554.
- 632 6. Coley, W. B. (1893). The treatment of malignant tumors by repeated inoculations of

- 633 erysipelas: With a report of ten original cases. 1. *The American Journal of the Medical*
634 *Sciences*, 105(6), 487.
635 [https://search.proquest.com/openview/09fb106c24157c028c895edfa8049551/1?pq-](https://search.proquest.com/openview/09fb106c24157c028c895edfa8049551/1?pq-origsite=gscholar&cbl=41361)
636 [origsite=gscholar&cbl=41361](https://search.proquest.com/openview/09fb106c24157c028c895edfa8049551/1?pq-origsite=gscholar&cbl=41361)
- 637 7. Starnes, C. O. (1992). Coley's toxins in perspective. *Nature*, 357(6373), 11–12.
638 <https://doi.org/10.1038/357011a0>
- 639 8. Hobohm, U. (2001). Fever and cancer in perspective. *Cancer Immunology, Immunotherapy:*
640 *CII*, 50(8), 391–396. <https://doi.org/10.1007/s002620100216>
- 641 9. Unproven Methods of Cancer Treatment. (1961). *CA: A Cancer Journal for Clinicians*, 11(5),
642 191–193. <https://doi.org/10.3322/canjclin.11.5.191>
- 643 10. Gopalakrishnan, V., Helmink, B. A., Spencer, C. N., Reuben, A., & Wargo, J. A. (2018). The
644 Influence of the Gut Microbiome on Cancer, Immunity, and Cancer Immunotherapy. *Cancer*
645 *Cell*, 33(4), 570–580. <https://doi.org/10.1016/j.ccell.2018.03.015>
- 646 11. Zitvogel, L., Ma, Y., Raoult, D., Kroemer, G., & Gajewski, T. F. (2018). The microbiome in
647 cancer immunotherapy: Diagnostic tools and therapeutic strategies. *Science*, 359(6382),
648 1366–1370. <https://doi.org/10.1126/science.aar6918>
- 649 12. Gopalakrishnan, V., Spencer, C. N., Nezi, L., Reuben, A., Andrews, M. C., Karpinets, T. V.,
650 Prieto, P. A., Vicente, D., Hoffman, K., Wei, S. C., Cogdill, A. P., Zhao, L., Hudgens, C. W.,
651 Hutchinson, D. S., Manzo, T., Petaccia de Macedo, M., Cotechini, T., Kumar, T., Chen, W.
652 S., ... Wargo, J. A. (2018). Gut microbiome modulates response to anti-PD-1
653 immunotherapy in melanoma patients. *Science*, 359(6371), 97–103.
654 <https://doi.org/10.1126/science.aan4236>
- 655 13. Routy, B., Le Chatelier, E., Derosa, L., Duong, C. P. M., Alou, M. T., Daillère, R., Fluckiger,
656 A., Messaoudene, M., Rauber, C., Roberti, M. P., Fidelle, M., Flament, C., Poirier-Colame,
657 V., Opolon, P., Klein, C., Iribarren, K., Mondragón, L., Jacquelot, N., Qu, B., ... Zitvogel, L.
658 (2018). Gut microbiome influences efficacy of PD-1-based immunotherapy against

- 659 epithelial tumors. *Science*, 359(6371), 91–97. <https://doi.org/10.1126/science.aan3706>
- 660 14. Matson, V., Fessler, J., Bao, R., Chongsuwat, T., Zha, Y., Alegre, M.-L., Luke, J. J., &
661 Gajewski, T. F. (2018). The commensal microbiome is associated with anti-PD-1 efficacy in
662 metastatic melanoma patients. *Science*, 359(6371), 104–108.
663 <https://doi.org/10.1126/science.aao3290>
- 664 15. Davar, D., Dzutsev, A. K., McCulloch, J. A., Rodrigues, R. R., Chauvin, J.-M., Morrison, R.
665 M., Deblasio, R. N., Menna, C., Ding, Q., Pagliano, O., Zidi, B., Zhang, S., Badger, J. H.,
666 Vetizou, M., Cole, A. M., Fernandes, M. R., Prescott, S., Costa, R. G. F., Balaji, A. K., ...
667 Zarour, H. M. (2021). Fecal microbiota transplant overcomes resistance to anti-PD-1
668 therapy in melanoma patients. *Science*, 371(6529), 595–602.
669 <https://doi.org/10.1126/science.abf3363>
- 670 16. Baruch, E. N., Youngster, I., Ben-Betzalel, G., Ortenberg, R., Lahat, A., Katz, L., Adler, K.,
671 Dick-Necula, D., Raskin, S., Bloch, N., Rotin, D., Anafi, L., Avivi, C., Melnichenko, J.,
672 Steinberg-Silman, Y., Mamtani, R., Harati, H., Asher, N., Shapira-Frommer, R., ... Boursi,
673 B. (2020). Fecal microbiota transplant promotes response in immunotherapy-refractory
674 melanoma patients. *Science*. <https://doi.org/10.1126/science.abb5920>
- 675 17. White, M. K., Pagano, J. S., & Khalili, K. (2014). Viruses and human cancers: a long road of
676 discovery of molecular paradigms. *Clinical Microbiology Reviews*, 27(3), 463–481.
677 <https://doi.org/10.1128/CMR.00124-13>
- 678 18. Rous, P. (1911). A SARCOMA OF THE FOWL TRANSMISSIBLE BY AN AGENT
679 SEPARABLE FROM THE TUMOR CELLS. *The Journal of Experimental Medicine*, 13(4),
680 397–411. <https://doi.org/10.1084/jem.13.4.397>
- 681 19. Martin, G. S. (2004). The road to Src. *Oncogene*, 23(48), 7910–7917.
682 <https://doi.org/10.1038/sj.onc.1208077>
- 683 20. Stehelin, D., Varmus, H. E., Bishop, J. M., & Vogt, P. K. (1976). DNA related to the
684 transforming gene(s) of avian sarcoma viruses is present in normal avian DNA. *Nature*,

- 685 260(5547), 170–173. <https://doi.org/10.1038/260170a0>
- 686 21. Dulbecco, R. (1986). A turning point in cancer research: sequencing the human genome.
687 *Science*, 231(4742), 1055–1056. <https://doi.org/10.1126/science.3945817>
- 688 22. Simons, P. J., & Dougherty, R. M. (1963). ANTIGENIC CHARACTERISTICS OF THREE
689 VARIANTS OF ROUS SARCOMA VIRUS. *Journal of the National Cancer Institute*, 31,
690 1275–1283. <https://www.ncbi.nlm.nih.gov/pubmed/14071832>
- 691 23. Svet-Moldavsky, G. J. (1957). Development of multiple cysts and of haemorrhagic affections
692 of internal organs in albino rats treated during the embryonic or new-born period with Rous
693 sarcoma virus. *Nature*, 180(4597), 1299–1300. <https://www.nature.com/articles/1801299a0>
- 694 24. Mulligan, R. C., & Berg, P. (1980). Expression of a bacterial gene in mammalian cells.
695 *Science*, 209(4463), 1422–1427. <https://doi.org/10.1126/science.6251549>
- 696 25. Grillot-Courvalin, C., Goussard, S., Huetz, F., Ojcius, D. M., & Courvalin, P. (1998).
697 Functional gene transfer from intracellular bacteria to mammalian cells. *Nature*
698 *Biotechnology*, 16(9), 862–866. <https://doi.org/10.1038/nbt0998-862>
- 699 26. Laner, A., Goussard, S., Ramalho, A. S., Schwarz, T., Amaral, M. D., Courvalin, P.,
700 Schindelbauer, D., & Grillot-Courvalin, C. (2005). Bacterial transfer of large functional
701 genomic DNA into human cells. *Gene Therapy*, 12(21), 1559–1572.
702 <https://doi.org/10.1038/sj.gt.3302576>
- 703 27. Darji, A., Guzmán, C. A., Gerstel, B., Wachholz, P., Timmis, K. N., Wehland, J.,
704 Chakraborty, T., & Weiss, S. (1997). Oral somatic transgene vaccination using attenuated
705 *S. typhimurium*. *Cell*, 91(6), 765–775. [https://doi.org/10.1016/s0092-8674\(00\)80465-1](https://doi.org/10.1016/s0092-8674(00)80465-1)
- 706 28. Sizemore, D. R., Branstrom, A. A., & Sadoff, J. C. (1995). Attenuated *Shigella* as a DNA
707 delivery vehicle for DNA-mediated immunization. *Science*, 270(5234), 299–302.
708 <https://doi.org/10.1126/science.270.5234.299>
- 709 29. Johnson, S. A., Ormsby, M. J., McIntosh, A., Tait, S. W. G., Blyth, K., & Wall, D. M. (2019).
710 Increasing the bactofection capacity of a mammalian expression vector by removal of the f1

- 711 ori. *Cancer Gene Therapy*, 26(7-8), 183–194. <https://doi.org/10.1038/s41417-018-0039-9>
- 712 30. Pálffy, R., Gardlík, R., Hodosy, J., Behuliak, M., Resko, P., Radvánský, J., & Celec, P.
713 (2006). Bacteria in gene therapy: bactofection versus alternative gene therapy. *Gene*
714 *Therapy*, 13(2), 101–105. <https://doi.org/10.1038/sj.gt.3302635>
- 715 31. Baban, C. K., Cronin, M., O’Hanlon, D., O’Sullivan, G. C., & Tangney, M. (2010). Bacteria as
716 vectors for gene therapy of cancer. *Bioengineered Bugs*, 1(6), 385–394.
717 <https://doi.org/10.4161/bbug.1.6.13146>
- 718 32. ICGC/TCGA Pan-Cancer Analysis of Whole Genomes Consortium. (2020). Pan-cancer
719 analysis of whole genomes. *Nature*, 578(7793), 82–93. [https://doi.org/10.1038/s41586-020-](https://doi.org/10.1038/s41586-020-1969-6)
720 1969-6
- 721 33. Li, Y., Roberts, N. D., Wala, J. A., Shapira, O., Schumacher, S. E., Kumar, K., Khurana, E.,
722 Waszak, S., Korbek, J. O., Haber, J. E., Imielinski, M., PCAWG Structural Variation Working
723 Group, Weischenfeldt, J., Beroukhim, R., Campbell, P. J., & PCAWG Consortium. (2020).
724 Patterns of somatic structural variation in human cancer genomes. *Nature*, 578(7793), 112–
725 121. <https://doi.org/10.1038/s41586-019-1913-9>
- 726 34. PCAWG Transcriptome Core Group, Calabrese, C., Davidson, N. R., Demircioğlu, D.,
727 Fonseca, N. A., He, Y., Kahles, A., Lehmann, K.-V., Liu, F., Shiraishi, Y., Soulette, C. M.,
728 Urban, L., Greger, L., Li, S., Liu, D., Perry, M. D., Xiang, Q., Zhang, F., Zhang, J., ...
729 PCAWG Consortium. (2020). Genomic basis for RNA alterations in cancer. *Nature*,
730 578(7793), 129–136. <https://doi.org/10.1038/s41586-020-1970-0>
- 731 35. Rheinbay, E., Nielsen, M. M., Abascal, F., Wala, J. A., Shapira, O., Tiao, G., Hornshøj, H.,
732 Hess, J. M., Juul, R. I., Lin, Z., Feuerbach, L., Sabarinathan, R., Madsen, T., Kim, J.,
733 Mularoni, L., Shuai, S., Lanzós, A., Herrmann, C., Maruvka, Y. E., ... PCAWG Consortium.
734 (2020). Analyses of non-coding somatic drivers in 2,658 cancer whole genomes. *Nature*,
735 578(7793), 102–111. <https://doi.org/10.1038/s41586-020-1965-x>
- 736 36. Cortés-Ciriano, I., Lee, J. J.-K., Xi, R., Jain, D., Jung, Y. L., Yang, L., Gordenin, D.,

- 737 Klimczak, L. J., Zhang, C.-Z., Pellman, D. S., PCAWG Structural Variation Working Group,
738 Park, P. J., & PCAWG Consortium. (2020). Comprehensive analysis of chromothripsis in
739 2,658 human cancers using whole-genome sequencing. *Nature Genetics*, 52(3), 331–341.
740 <https://doi.org/10.1038/s41588-019-0576-7>
- 741 37. McGranahan, N., & Swanton, C. (2017). Clonal Heterogeneity and Tumor Evolution: Past,
742 Present, and the Future. *Cell*, 168(4), 613–628. <https://doi.org/10.1016/j.cell.2017.01.018>
- 743 38. Black, J. R. M., & McGranahan, N. (2021). Genetic and non-genetic clonal diversity in
744 cancer evolution. *Nature Reviews. Cancer*, 21(6), 379–392. [https://doi.org/10.1038/s41568-](https://doi.org/10.1038/s41568-021-00336-2)
745 [021-00336-2](https://doi.org/10.1038/s41568-021-00336-2)
- 746 39. Hanahan, D., & Weinberg, R. A. (2011). Hallmarks of cancer: the next generation. *Cell*,
747 144(5), 646–674. <https://doi.org/10.1016/j.cell.2011.02.013>
- 748 40. Turner, K. M., Deshpande, V., Beyter, D., Koga, T., Rusert, J., Lee, C., Li, B., Arden, K.,
749 Ren, B., Nathanson, D. A., Kornblum, H. I., Taylor, M. D., Kaushal, S., Cavenee, W. K.,
750 Wechsler-Reya, R., Furnari, F. B., Vandenberg, S. R., Rao, P. N., Wahl, G. M., ... Mischel,
751 P. S. (2017). Extrachromosomal oncogene amplification drives tumour evolution and
752 genetic heterogeneity. *Nature*, 543(7643), 122–125. <https://doi.org/10.1038/nature21356>
- 753 41. Wu, S., Turner, K. M., Nguyen, N., Raviram, R., Erb, M., Santini, J., Luebeck, J., Rajkumar,
754 U., Diao, Y., Li, B., Zhang, W., Jameson, N., Corces, M. R., Granja, J. M., Chen, X., Coruh,
755 C., Abnoui, A., Houston, J., Ye, Z., ... Mischel, P. S. (2019). Circular ecDNA promotes
756 accessible chromatin and high oncogene expression. *Nature*, 575(7784), 699–703.
757 <https://doi.org/10.1038/s41586-019-1763-5>
- 758 42. Kim, H., Nguyen, N.-P., Turner, K., Wu, S., Gujar, A. D., Luebeck, J., Liu, J., Deshpande, V.,
759 Rajkumar, U., Namburi, S., & Others. (2020). Extrachromosomal DNA is associated with
760 oncogene amplification and poor outcome across multiple cancers. *Nature Genetics*, 52(9),
761 891–897. <https://www.nature.com/articles/s41588-020-0678-2>
- 762 43. Verhaak, R. G. W., Bafna, V., & Mischel, P. S. (2019). Extrachromosomal oncogene

- 763 amplification in tumour pathogenesis and evolution. *Nature Reviews. Cancer*, 19(5), 283–
764 288. <https://doi.org/10.1038/s41568-019-0128-6>
- 765 44. Münch, K., Münch, R., Biedendieck, R., Jahn, D., & Müller, J. (2019). Evolutionary model for
766 the unequal segregation of high copy plasmids. *PLoS Computational Biology*, 15(3),
767 e1006724. <https://doi.org/10.1371/journal.pcbi.1006724>
- 768 45. Deshpande, V., Luebeck, J., Nguyen, N.-P. D., Bakhtiari, M., Turner, K. M., Schwab, R.,
769 Carter, H., Mischel, P. S., & Bafna, V. (2019). Exploring the landscape of focal
770 amplifications in cancer using AmpliconArchitect. *Nature Communications*, 10(1), 392.
771 <https://doi.org/10.1038/s41467-018-08200-y>
- 772 46. Pang, J., Nguyen, N.-P., Luebeck, J., Ball, L., Finegersh, A., Ren, S., Nakagawa, T., Flagg,
773 M., Sadat, S., Mischel, P. S., Xu, G., Fisch, K., Guo, T., Cahill, G., Panuganti, B., Bafna, V.,
774 & Califano, J. (2021). Extrachromosomal DNA in HPV mediated oropharyngeal cancer
775 drives diverse oncogene transcription. *Clinical Cancer Research: An Official Journal of the*
776 *American Association for Cancer Research*. [https://doi.org/10.1158/1078-0432.CCR-21-](https://doi.org/10.1158/1078-0432.CCR-21-2484)
777 2484
- 778 47. Geller, L. T., Barzily-Rokni, M., Danino, T., Jonas, O. H., Shental, N., Nejman, D., Gavert,
779 N., Zwang, Y., Cooper, Z. A., Shee, K., Thaiss, C. A., Reuben, A., Livny, J., Avraham, R.,
780 Frederick, D. T., Ligorio, M., Chatman, K., Johnston, S. E., Mosher, C. M., ... Straussman,
781 R. (2017). Potential role of intratumor bacteria in mediating tumor resistance to the
782 chemotherapeutic drug gemcitabine. *Science*, 357(6356), 1156–1160.
783 <https://doi.org/10.1126/science.aah5043>
- 784 48. Pushalkar, S., Hundeyin, M., Daley, D., Zambirinis, C. P., Kurz, E., Mishra, A., Mohan, N.,
785 Aykut, B., Usyk, M., Torres, L. E., Werba, G., Zhang, K., Guo, Y., Li, Q., Akkad, N., Lall, S.,
786 Wadowski, B., Gutierrez, J., Kochen Rossi, J. A., ... Miller, G. (2018). The Pancreatic
787 Cancer Microbiome Promotes Oncogenesis by Induction of Innate and Adaptive Immune
788 Suppression. *Cancer Discovery*, 8(4), 403–416. <https://doi.org/10.1158/2159-8290.CD-17->

- 789 1134
- 790 49. Kalaora, S., Nagler, A., Nejman, D., Alon, M., Barbolin, C., Barnea, E., Ketelaars, S. L. C.,
791 Cheng, K., Vervier, K., Shental, N., Bussi, Y., Rotkopf, R., Levy, R., Benedek, G., Trabish,
792 S., Dadosh, T., Levin-Zaidman, S., Geller, L. T., Wang, K., ... Samuels, Y. (2021).
793 Identification of bacteria-derived HLA-bound peptides in melanoma. *Nature*, *592*(7852),
794 138–143. <https://doi.org/10.1038/s41586-021-03368-8>
- 795 50. Jin, C., Lagoudas, G. K., Zhao, C., Bullman, S., Bhutkar, A., Hu, B., Ameh, S., Sandel, D.,
796 Liang, X. S., Mazzilli, S., Whary, M. T., Meyerson, M., Germain, R., Blainey, P. C., Fox, J.
797 G., & Jacks, T. (2019). Commensal Microbiota Promote Lung Cancer Development via $\gamma\delta$ T
798 Cells. *Cell*, *176*(5), 998–1013.e16. <https://doi.org/10.1016/j.cell.2018.12.040>
- 799 51. Tsay, J.-C. J., Wu, B. G., Sulaiman, I., Gershner, K., Schluger, R., Li, Y., Yie, T.-A., Meyn,
800 P., Olsen, E., Perez, L., Franca, B., Carpenito, J., Iizumi, T., El-Ashmawy, M., Badri, M.,
801 Morton, J. T., Shen, N., He, L., Michaud, G., ... Segal, L. N. (2021). Lower Airway
802 Dysbiosis Affects Lung Cancer Progression. *Cancer Discovery*, *11*(2), 293–307.
803 <https://doi.org/10.1158/2159-8290.CD-20-0263>
- 804 52. Riquelme, E., Zhang, Y., Zhang, L., Montiel, M., Zoltan, M., Dong, W., Quesada, P., Sahin,
805 I., Chandra, V., San Lucas, A., Scheet, P., Xu, H., Hanash, S. M., Feng, L., Burks, J. K.,
806 Do, K.-A., Peterson, C. B., Nejman, D., Tzeng, C.-W. D., ... McAllister, F. (2019). Tumor
807 Microbiome Diversity and Composition Influence Pancreatic Cancer Outcomes. *Cell*,
808 *178*(4), 795–806.e12. <https://doi.org/10.1016/j.cell.2019.07.008>
- 809 53. Parhi, L., Alon-Maimon, T., Sol, A., Nejman, D., Shhadeh, A., Fainsod-Levi, T., Yajuk, O.,
810 Isaacson, B., Abed, J., Maalouf, N., Nissan, A., Sandbank, J., Yehuda-Shnaidman, E.,
811 Ponath, F., Vogel, J., Mandelboim, O., Granot, Z., Straussman, R., & Bachrach, G. (2020).
812 Breast cancer colonization by *Fusobacterium nucleatum* accelerates tumor growth and
813 metastatic progression. *Nature Communications*, *11*(1), 3259.
814 <https://doi.org/10.1038/s41467-020-16967-2>

- 815 54. Le Noci, V., Guglielmetti, S., Arioli, S., Camisaschi, C., Bianchi, F., Sommariva, M., Storti,
816 C., Triulzi, T., Castelli, C., Balsari, A., Tagliabue, E., & Sfondrini, L. (2018). Modulation of
817 Pulmonary Microbiota by Antibiotic or Probiotic Aerosol Therapy: A Strategy to Promote
818 Immunosurveillance against Lung Metastases. *Cell Reports*, 24(13), 3528–3538.
819 <https://doi.org/10.1016/j.celrep.2018.08.090>
- 820 55. Shi, Y., Zheng, W., Yang, K., Harris, K. G., Ni, K., Xue, L., Lin, W., Chang, E. B.,
821 Weichselbaum, R. R., & Fu, Y.-X. (2020). Intratumoral accumulation of gut microbiota
822 facilitates CD47-based immunotherapy via STING signaling. *The Journal of Experimental*
823 *Medicine*, 217(5). <https://doi.org/10.1084/jem.20192282>
- 824 56. Mima, K., Sukawa, Y., Nishihara, R., Qian, Z. R., Yamauchi, M., Inamura, K., Kim, S. A.,
825 Masuda, A., Nowak, J. A., Nosho, K., Kostic, A. D., Giannakis, M., Watanabe, H., Bullman,
826 S., Milner, D. A., Harris, C. C., Giovannucci, E., Garraway, L. A., Freeman, G. J., ... Ogino,
827 S. (2015). *Fusobacterium nucleatum* and T Cells in Colorectal Carcinoma. *JAMA Oncology*,
828 1(5), 653–661. <https://doi.org/10.1001/jamaoncol.2015.1377>
- 829 57. Nejman, D., Livyatan, I., Fuks, G., Gavert, N., Zwang, Y., Geller, L. T., Rotter-Maskowitz, A.,
830 Weiser, R., Mallel, G., Gigi, E., Meltser, A., Douglas, G. M., Kaminer, I., Gopalakrishnan, V.,
831 Dadosh, T., Levin-Zaidman, S., Avnet, S., Atlan, T., Cooper, Z. A., ... Straussman, R.
832 (2020). The human tumor microbiome is composed of tumor type-specific intracellular
833 bacteria. *Science*, 368(6494), 973–980. <https://doi.org/10.1126/science.aay9189>
- 834 58. Poore, G. D., Kopylova, E., Zhu, Q., Carpenter, C., Fraraccio, S., Wandro, S., Kosciulek, T.,
835 Janssen, S., Metcalf, J., Song, S. J., Kanbar, J., Miller-Montgomery, S., Heaton, R., McKay,
836 R., Patel, S. P., Swafford, A. D., & Knight, R. (2020). Microbiome analyses of blood and
837 tissues suggest cancer diagnostic approach. *Nature*, 579(7800), 567–574.
838 <https://doi.org/10.1038/s41586-020-2095-1>
- 839 59. Wieland, A., Patel, M. R., Cardenas, M. A., Eberhardt, C. S., Hudson, W. H., Obeng, R. C.,
840 Griffith, C. C., Wang, X., Chen, Z. G., Kissick, H. T., Saba, N. F., & Ahmed, R. (2021).

- 841 Defining HPV-specific B cell responses in patients with head and neck cancer. *Nature*,
842 597(7875), 274–278. <https://doi.org/10.1038/s41586-020-2931-3>
- 843 60. Zapatka, M., Borozan, I., Brewer, D. S., Iskar, M., Grundhoff, A., Alawi, M., Desai, N.,
844 Sültmann, H., Moch, H., PCAWG Pathogens, Cooper, C. S., Eils, R., Ferretti, V., Lichter,
845 P., & PCAWG Consortium. (2020). The landscape of viral associations in human cancers.
846 *Nature Genetics*, 52(3), 320–330. <https://doi.org/10.1038/s41588-019-0558-9>
- 847 61. Bullman, S., Pedamallu, C. S., Sicinska, E., Clancy, T. E., Zhang, X., Cai, D., Neuberg, D.,
848 Huang, K., Guevara, F., Nelson, T., Chipashvili, O., Hagan, T., Walker, M., Ramachandran,
849 A., Diosdado, B., Serna, G., Mulet, N., Landolfi, S., Ramon Y Cajal, S., ... Meyerson, M.
850 (2017). Analysis of *Fusobacterium* persistence and antibiotic response in colorectal cancer.
851 *Science*, 358(6369), 1443–1448. <https://doi.org/10.1126/science.aal5240>
- 852 62. Bertocchi, A., Carloni, S., Ravenda, P. S., Bertalot, G., Spadoni, I., Lo Cascio, A., Gandini,
853 S., Lizier, M., Braga, D., Asnicar, F., Segata, N., Klaver, C., Brescia, P., Rossi, E.,
854 Anselmo, A., Guglietta, S., Maroli, A., Spaggiari, P., Tarazona, N., ... Rescigno, M. (2021).
855 Gut vascular barrier impairment leads to intestinal bacteria dissemination and colorectal
856 cancer metastasis to liver. *Cancer Cell*, 39(5), 708–724.e11.
857 <https://doi.org/10.1016/j.ccell.2021.03.004>
- 858 63. Casasanta, M. A., Yoo, C. C., Udayasuryan, B., Sanders, B. E., Umaña, A., Zhang, Y.,
859 Peng, H., Duncan, A. J., Wang, Y., Li, L., Verbridge, S. S., & Slade, D. J. (2020).
860 *Fusobacterium nucleatum* host-cell binding and invasion induces IL-8 and CXCL1 secretion
861 that drives colorectal cancer cell migration. In *Science Signaling* (Vol. 13, Issue 641, p.
862 eaba9157). <https://doi.org/10.1126/scisignal.aba9157>
- 863 64. Shiao, S. L., Kershaw, K. M., Limon, J. J., You, S., Yoon, J., Ko, E. Y., Guarnerio, J., Potdar,
864 A. A., McGovern, D. P. B., Bose, S., Dar, T. B., Noe, P., Lee, J., Kubota, Y., Maymi, V. I.,
865 Davis, M. J., Henson, R. M., Choi, R. Y., Yang, W., ... Underhill, D. M. (2021). Commensal
866 bacteria and fungi differentially regulate tumor responses to radiation therapy. *Cancer Cell*,

- 867 39(9), 1202–1213.e6. <https://doi.org/10.1016/j.ccell.2021.07.002>
- 868 65. Pernigoni, N., Zagato, E., Calcinotto, A., Troiani, M., Mestre, R. P., Cali, B., Attanasio, G.,
869 Troisi, J., Minini, M., Mosole, S., Revandkar, A., Pasquini, E., Elia, A. R., Bossi, D., Rinaldi,
870 A., Rescigno, P., Flohr, P., Hunt, J., Neeb, A., ... Alimonti, A. (2021). Commensal bacteria
871 promote endocrine resistance in prostate cancer through androgen biosynthesis. *Science*,
872 374(6564), 216–224. <https://doi.org/10.1126/science.abf8403>
- 873 66. Viaud, S., Saccheri, F., Mignot, G., Yamazaki, T., Daillère, R., Hannani, D., Enot, D. P.,
874 Pfirschke, C., Engblom, C., Pittet, M. J., Schlitzer, A., Ginhoux, F., Apetoh, L., Chachaty,
875 E., Woerther, P.-L., Eberl, G., Bérard, M., Ecobichon, C., Clermont, D., ... Zitvogel, L.
876 (2013). The intestinal microbiota modulates the anticancer immune effects of
877 cyclophosphamide. *Science*, 342(6161), 971–976. <https://doi.org/10.1126/science.1240537>
- 878 67. Iida, N., Dzutsev, A., Stewart, C. A., Smith, L., Bouladoux, N., Weingarten, R. A., Molina, D.
879 A., Salcedo, R., Back, T., Cramer, S., Dai, R.-M., Kiu, H., Cardone, M., Naik, S., Patri, A.
880 K., Wang, E., Marincola, F. M., Frank, K. M., Belkaid, Y., ... Goldszmid, R. S. (2013).
881 Commensal bacteria control cancer response to therapy by modulating the tumor
882 microenvironment. *Science*, 342(6161), 967–970. <https://doi.org/10.1126/science.1240527>
- 883 68. Di Modica, M., Gargari, G., Regondi, V., Bonizzi, A., Arioli, S., Belmonte, B., De Cecco, L.,
884 Fasano, E., Bianchi, F., Bertolotti, A., Tripodo, C., Villani, L., Corsi, F., Guglielmetti, S.,
885 Balsari, A., Triulzi, T., & Tagliabue, E. (2021). Gut Microbiota Condition the Therapeutic
886 Efficacy of Trastuzumab in HER2-Positive Breast Cancer. *Cancer Research*, 81(8), 2195–
887 2206. <https://doi.org/10.1158/0008-5472.CAN-20-1659>
- 888 69. Kwong, T. N. Y., Wang, X., Nakatsu, G., Chow, T. C., Tipoe, T., Dai, R. Z. W., Tsoi, K. K. K.,
889 Wong, M. C. S., Tse, G., Chan, M. T. V., Chan, F. K. L., Ng, S. C., Wu, J. C. Y., Wu, W. K.
890 K., Yu, J., Sung, J. J. Y., & Wong, S. H. (2018). Association Between Bacteremia From
891 Specific Microbes and Subsequent Diagnosis of Colorectal Cancer. *Gastroenterology*,
892 155(2), 383–390.e8. <https://doi.org/10.1053/j.gastro.2018.04.028>

- 893 70. Sender, R., Fuchs, S., & Milo, R. (2016). Revised Estimates for the Number of Human and
894 Bacteria Cells in the Body. *PLoS Biology*, *14*(8), e1002533.
895 <https://doi.org/10.1371/journal.pbio.1002533>
- 896 71. Belkaid, Y., & Naik, S. (2013). Compartmentalized and systemic control of tissue immunity
897 by commensals. *Nature Immunology*, *14*(7), 646–653. <https://doi.org/10.1038/ni.2604>
- 898 72. Ramírez-Flandes, S., González, B., & Ulloa, O. (2019). Redox traits characterize the
899 organization of global microbial communities. *Proceedings of the National Academy of*
900 *Sciences of the United States of America*, *116*(9), 3630–3635.
901 <https://doi.org/10.1073/pnas.1817554116>
- 902 73. Almeida, A., Nayfach, S., Boland, M., Strozzi, F., Beracochea, M., Shi, Z. J., Pollard, K. S.,
903 Sakharova, E., Parks, D. H., Hugenholtz, P., Segata, N., Kyrpides, N. C., & Finn, R. D.
904 (2021). A unified catalog of 204,938 reference genomes from the human gut microbiome.
905 *Nature Biotechnology*, *39*(1), 105–114. <https://doi.org/10.1038/s41587-020-0603-3>
- 906 74. Dion, M. B., Oechslin, F., & Moineau, S. (2020). Phage diversity, genomics and phylogeny.
907 *Nature Reviews. Microbiology*, *18*(3), 125–138. <https://doi.org/10.1038/s41579-019-0311-5>
- 908 75. Sender, R., Fuchs, S., & Milo, R. (2016). Are We Really Vastly Outnumbered? Revisiting the
909 Ratio of Bacterial to Host Cells in Humans. *Cell*, *164*(3), 337–340.
910 <https://doi.org/10.1016/j.cell.2016.01.013>
- 911 76. Erdag, G., Schaefer, J. T., Smolkin, M. E., Deacon, D. H., Shea, S. M., Dengel, L. T.,
912 Patterson, J. W., & Slingsluff, C. L., Jr. (2012). Immunotype and immunohistologic
913 characteristics of tumor-infiltrating immune cells are associated with clinical outcome in
914 metastatic melanoma. *Cancer Research*, *72*(5), 1070–1080. <https://doi.org/10.1158/0008-5472.CAN-11-3218>
- 915
- 916 77. Stephenson, K. (2005). *Introduction to Circle Packing: The Theory of Discrete Analytic*
917 *Functions*. Cambridge University Press.
918 <https://play.google.com/store/books/details?id=38PxEmKKhysC>

- 919 78. Downey, G. P., Doherty, D. E., Schwab, B., 3rd, Elson, E. L., Henson, P. M., & Worthen, G.
920 S. (1990). Retention of leukocytes in capillaries: role of cell size and deformability. *Journal*
921 *of Applied Physiology*, 69(5), 1767–1778. <https://doi.org/10.1152/jappl.1990.69.5.1767>
- 922 79. Shashni, B., Ariyasu, S., Takeda, R., Suzuki, T., Shiina, S., Akimoto, K., Maeda, T., Aikawa,
923 N., Abe, R., Osaki, T., Itoh, N., & Aoki, S. (2018). Size-Based Differentiation of Cancer and
924 Normal Cells by a Particle Size Analyzer Assisted by a Cell-Recognition PC Software.
925 *Biological & Pharmaceutical Bulletin*, 41(4), 487–503. [https://doi.org/10.1248/bpb.b17-](https://doi.org/10.1248/bpb.b17-00776)
926 00776
- 927 80. Kather, J. N., Suarez-Carmona, M., Charoentong, P., Weis, C.-A., Hirsch, D., Bankhead, P.,
928 Horning, M., Ferber, D., Kel, I., Herpel, E., Schott, S., Zörnig, I., Utikal, J., Marx, A., Gaiser,
929 T., Brenner, H., Chang-Claude, J., Hoffmeister, M., Jäger, D., & Halama, N. (2018).
930 Topography of cancer-associated immune cells in human solid tumors. *eLife*, 7.
931 <https://doi.org/10.7554/eLife.36967>
- 932 81. Monte, U. D., & Del Monte, U. (2009). Does the cell number 10⁹ still really fit one gram of
933 tumor tissue? In *Cell Cycle* (Vol. 8, Issue 3, pp. 505–506).
934 <https://doi.org/10.4161/cc.8.3.7608>
- 935 82. Avanzini, S., Kurtz, D. M., Chabon, J. J., Moding, E. J., Hori, S. S., Gambhir, S. S., Alizadeh,
936 A. A., Diehn, M., & Reiter, J. G. (2020). A mathematical model of ctDNA shedding predicts
937 tumor detection size. *Science Advances*, 6(50). <https://doi.org/10.1126/sciadv.abc4308>
- 938 83. Abbosh, C., Birkbak, N. J., Wilson, G. A., Jamal-Hanjani, M., Constantin, T., Salari, R., Le
939 Quesne, J., Moore, D. A., Veeriah, S., Rosenthal, R., Marafioti, T., Kirkizlar, E., Watkins, T.
940 B. K., McGranahan, N., Ward, S., Martinson, L., Riley, J., Fraioli, F., Al Bakir, M., ...
941 Swanton, C. (2017). Phylogenetic ctDNA analysis depicts early-stage lung cancer
942 evolution. *Nature*, 545(7655), 446–451. <https://doi.org/10.1038/nature22364>
- 943 84. Cristiano, S., Leal, A., Phallen, J., Fiksel, J., Adleff, V., Bruhm, D. C., Jensen, S. Ø., Medina,
944 J. E., Hruban, C., White, J. R., Palsgrove, D. N., Niknafs, N., Anagnostou, V., Forde, P.,

- 945 Naidoo, J., Marrone, K., Brahmer, J., Woodward, B. D., Husain, H., ... Velculescu, V. E.
946 (2019). Genome-wide cell-free DNA fragmentation in patients with cancer. *Nature*,
947 *570*(7761), 385–389. <https://doi.org/10.1038/s41586-019-1272-6>
- 948 85. Yachida, S., Mizutani, S., Shiroma, H., Shiba, S., Nakajima, T., Sakamoto, T., Watanabe,
949 H., Masuda, K., Nishimoto, Y., Kubo, M., Hosoda, F., Rokutan, H., Matsumoto, M.,
950 Takamaru, H., Yamada, M., Matsuda, T., Iwasaki, M., Yamaji, T., Yachida, T., ... Yamada,
951 T. (2019). Metagenomic and metabolomic analyses reveal distinct stage-specific
952 phenotypes of the gut microbiota in colorectal cancer. *Nature Medicine*, *25*(6), 968–976.
953 <https://doi.org/10.1038/s41591-019-0458-7>
- 954 86. Dadkhah, E., Sikaroodi, M., Korman, L., Hardi, R., Baybick, J., Hanzel, D., Kuehn, G.,
955 Kuehn, T., & Gillevet, P. M. (2019). Gut microbiome identifies risk for colorectal polyps.
956 *BMJ Open Gastroenterology*, *6*(1), e000297. <https://doi.org/10.1136/bmjgast-2019-000297>
- 957 87. Peters, B. A., Dominianni, C., Shapiro, J. A., Church, T. R., Wu, J., Miller, G., Yuen, E.,
958 Freiman, H., Lustbader, I., Salik, J., Friedlander, C., Hayes, R. B., & Ahn, J. (2016). The gut
959 microbiota in conventional and serrated precursors of colorectal cancer. *Microbiome*, *4*(1),
960 69. <https://doi.org/10.1186/s40168-016-0218-6>
- 961 88. Kordahi, M. C., Stanaway, I. B., Avril, M., Chac, D., Blanc, M.-P., Ross, B., Diener, C., Jain,
962 S., McCleary, P., Parker, A., Friedman, V., Huang, J., Burke, W., Gibbons, S. M., Willis, A.
963 D., Darveau, R. P., Grady, W. M., Ko, C. W., & DePaolo, R. W. (2021). Genomic and
964 functional characterization of a mucosal symbiont involved in early-stage colorectal cancer.
965 *Cell Host & Microbe*, *29*(10), 1589–1598.e6. <https://doi.org/10.1016/j.chom.2021.08.013>
- 966 89. Usyk, M., Zolnik, C. P., Castle, P. E., Porras, C., Herrero, R., Gradissimo, A., Gonzalez, P.,
967 Safaeian, M., Schiffman, M., Burk, R. D., & Costa Rica HPV Vaccine Trial (CVT) Group.
968 (2020). Cervicovaginal microbiome and natural history of HPV in a longitudinal study. *PLoS*
969 *Pathogens*, *16*(3), e1008376. <https://doi.org/10.1371/journal.ppat.1008376>
- 970 90. Tango, C. N., Seo, S.-S., Kwon, M., Lee, D.-O., Chang, H. K., & Kim, M. K. (2020).

- 971 Taxonomic and Functional Differences in Cervical Microbiome Associated with Cervical
 972 Cancer Development. *Scientific Reports*, 10(1), 9720. [https://doi.org/10.1038/s41598-020-](https://doi.org/10.1038/s41598-020-66607-4)
 973 66607-4
- 974 91. Klein, C., Gonzalez, D., Samwel, K., Kahesa, C., Mwaiselage, J., Aluthge, N., Fernando, S.,
 975 West, J. T., Wood, C., & Angeletti, P. C. (2019). Relationship between the Cervical
 976 Microbiome, HIV Status, and Precancerous Lesions. *mBio*, 10(1).
 977 <https://doi.org/10.1128/mBio.02785-18>
- 978 92. Delhommeau, F., Dupont, S., Della Valle, V., James, C., Trannoy, S., Massé, A., Kosmider,
 979 O., Le Couedic, J.-P., Robert, F., Alberdi, A., Lécluse, Y., Plo, I., Dreyfus, F. J., Marzac, C.,
 980 Casadevall, N., Lacombe, C., Romana, S. P., Dessen, P., Soulier, J., ... Bernard, O. A.
 981 (2009). Mutation in TET2 in myeloid cancers. *The New England Journal of Medicine*,
 982 360(22), 2289–2301. <https://doi.org/10.1056/NEJMoa0810069>
- 983 93. Dejea, C. M., Fathi, P., Craig, J. M., Boleij, A., Taddese, R., Geis, A. L., Wu, X., DeStefano
 984 Shields, C. E., Hechenbleikner, E. M., Huso, D. L., Anders, R. A., Giardiello, F. M., Wick, E.
 985 C., Wang, H., Wu, S., Pardoll, D. M., Housseau, F., & Sears, C. L. (2018). Patients with
 986 familial adenomatous polyposis harbor colonic biofilms containing tumorigenic bacteria.
 987 *Science*, 359(6375), 592–597. <https://doi.org/10.1126/science.aah3648>
- 988 94. Meisel, M., Hinterleitner, R., Pacis, A., Chen, L., Earley, Z. M., Mayassi, T., Pierre, J. F.,
 989 Ernest, J. D., Galipeau, H. J., Thuille, N., Bouziat, R., Buscarlet, M., Ringus, D. L., Wang,
 990 Y., Li, Y., Dinh, V., Kim, S. M., McDonald, B. D., Zurenski, M. A., ... Jabri, B. (2018).
 991 Microbial signals drive pre-leukaemic myeloproliferation in a Tet2-deficient host. *Nature*,
 992 557(7706), 580–584. <https://doi.org/10.1038/s41586-018-0125-z>
- 993 95. Nené, N. R., Reisel, D., Leimbach, A., Franchi, D., Jones, A., Evans, I., Knapp, S., Ryan, A.,
 994 Ghazali, S., Timms, J. F., Paprotka, T., Bjørge, L., Zikan, M., Cibula, D., Colombo, N., &
 995 Widschwendter, M. (2019). Association between the cervicovaginal microbiome, BRCA1
 996 mutation status, and risk of ovarian cancer: a case-control study. *The Lancet Oncology*,

- 997 20(8), 1171–1182. [https://doi.org/10.1016/S1470-2045\(19\)30340-7](https://doi.org/10.1016/S1470-2045(19)30340-7)
- 998 96. Davis, N. M., Proctor, D. M., Holmes, S. P., Relman, D. A., & Callahan, B. J. (2018). Simple
999 statistical identification and removal of contaminant sequences in marker-gene and
1000 metagenomics data. *Microbiome*, 6(1), 226. <https://doi.org/10.1186/s40168-018-0605-2>
- 1001 97. Klein, R. S., Recco, R. A., Catalano, M. T., Edberg, S. C., Casey, J. I., & Steigbigel, N. H.
1002 (1977). Association of *Streptococcus bovis* with carcinoma of the colon. *The New England*
1003 *Journal of Medicine*, 297(15), 800–802. <https://doi.org/10.1056/NEJM197710132971503>
- 1004 98. Abed, J., Emgård, J. E. M., Zamir, G., Faroja, M., Almogy, G., Grenov, A., Sol, A., Naor, R.,
1005 Pikarsky, E., Atlan, K. A., Mellul, A., Chaushu, S., Manson, A. L., Earl, A. M., Ou, N.,
1006 Brennan, C. A., Garrett, W. S., & Bachrach, G. (2016). Fap2 Mediates *Fusobacterium*
1007 *nucleatum* Colorectal Adenocarcinoma Enrichment by Binding to Tumor-Expressed Gal-
1008 GalNAc. *Cell Host & Microbe*, 20(2), 215–225. <https://doi.org/10.1016/j.chom.2016.07.006>
- 1009 99. Abed, J., Maalouf, N., Manson, A. L., Earl, A. M., Parhi, L., Emgård, J. E. M., Klutstein, M.,
1010 Tayeb, S., Almogy, G., Atlan, K. A., Chaushu, S., Israeli, E., Mandelboim, O., Garrett, W.
1011 S., & Bachrach, G. (2020). Colon Cancer-Associated *Fusobacterium nucleatum* May
1012 Originate From the Oral Cavity and Reach Colon Tumors via the Circulatory System.
1013 *Frontiers in Cellular and Infection Microbiology*, 10, 400.
1014 <https://doi.org/10.3389/fcimb.2020.00400>
- 1015 100. Sims, T. T., El Alam, M. B., Karpinets, T. V., Dorta-Estremera, S., Hegde, V. L., Nookala,
1016 S., Yoshida-Court, K., Wu, X., Biegert, G. W. G., Delgado Medrano, A. Y., Solley, T.,
1017 Ahmed-Kaddar, M., Chapman, B. V., Sastry, K. J., Mezzari, M. P., Petrosino, J. F., Lin, L.
1018 L., Ramondetta, L., Jhingran, A., ... Klopp, A. H. (2021). Gut microbiome diversity is an
1019 independent predictor of survival in cervical cancer patients receiving chemoradiation.
1020 *Communications Biology*, 4(1), 237. <https://doi.org/10.1038/s42003-021-01741-x>
- 1021 101. Peled, J. U., Gomes, A. L. C., Devlin, S. M., Littmann, E. R., Taur, Y., Sung, A. D., Weber,
1022 D., Hashimoto, D., Slingerland, A. E., Slingerland, J. B., Maloy, M., Clurman, A. G., Stein-

- 1023 Thoeringer, C. K., Markey, K. A., Docampo, M. D., Burgos da Silva, M., Khan, N., Gessner,
1024 A., Messina, J. A., ... van den Brink, M. R. M. (2020). Microbiota as Predictor of Mortality in
1025 Allogeneic Hematopoietic-Cell Transplantation. *The New England Journal of Medicine*,
1026 382(9), 822–834. <https://doi.org/10.1056/NEJMoa1900623>
- 1027 102. Vétizou, M., Pitt, J. M., Daillère, R., Lepage, P., Waldschmitt, N., Flament, C., Rusakiewicz,
1028 S., Routy, B., Roberti, M. P., Duong, C. P. M., Poirier-Colame, V., Roux, A., Becharef, S.,
1029 Formenti, S., Golden, E., Cording, S., Eberl, G., Schlitzer, A., Ginhoux, F., ... Zitvogel, L.
1030 (2015). Anticancer immunotherapy by CTLA-4 blockade relies on the gut microbiota.
1031 *Science*, 350(6264), 1079–1084. <https://doi.org/10.1126/science.aad1329>
- 1032 103. Sivan, A., Corrales, L., Hubert, N., Williams, J. B., Aquino-Michaels, K., Earley, Z. M.,
1033 Benyamin, F. W., Lei, Y. M., Jabri, B., Alegre, M.-L., Chang, E. B., & Gajewski, T. F. (2015).
1034 Commensal *Bifidobacterium* promotes antitumor immunity and facilitates anti-PD-L1
1035 efficacy. *Science*, 350(6264), 1084–1089. <https://doi.org/10.1126/science.aac4255>
- 1036 104. Limeta, A., Ji, B., Levin, M., Gatto, F., & Nielsen, J. (2020). Meta-analysis of the gut
1037 microbiota in predicting response to cancer immunotherapy in metastatic melanoma. *JCI*
1038 *Insight*, 5(23). <https://doi.org/10.1172/jci.insight.140940>
- 1039 105. Mager, L. F., Burkhard, R., Pett, N., Cooke, N. C. A., Brown, K., Ramay, H., Paik, S.,
1040 Stagg, J., Groves, R. A., Gallo, M., Lewis, I. A., Geuking, M. B., & McCoy, K. D. (2020).
1041 Microbiome-derived inosine modulates response to checkpoint inhibitor immunotherapy.
1042 *Science*, 369(6510), 1481–1489. <https://doi.org/10.1126/science.abc3421>
- 1043 106. Griffin, M. E., Espinosa, J., Becker, J. L., Luo, J.-D., Carroll, T. S., Jha, J. K., Fanger, G.
1044 R., & Hang, H. C. (2021). Enterococcus peptidoglycan remodeling promotes checkpoint
1045 inhibitor cancer immunotherapy. *Science*, 373(6558), 1040–1046.
1046 <https://doi.org/10.1126/science.abc9113>
- 1047 107. Daillère, R., Vétizou, M., Waldschmitt, N., Yamazaki, T., Isnard, C., Poirier-Colame, V.,
1048 Duong, C. P. M., Flament, C., Lepage, P., Roberti, M. P., Routy, B., Jacquelot, N., Apetoh,

- 1049 L., Becharef, S., Rusakiewicz, S., Langella, P., Sokol, H., Kroemer, G., Enot, D., ...
1050 Zitvogel, L. (2016). Enterococcus hirae and Barnesiella intestinihominis Facilitate
1051 Cyclophosphamide-Induced Therapeutic Immunomodulatory Effects. *Immunity*, 45(4), 931–
1052 943. <https://doi.org/10.1016/j.immuni.2016.09.009>
- 1053 108. Lam, K. C., Araya, R. E., Huang, A., Chen, Q., Di Modica, M., Rodrigues, R. R., Lopès, A.,
1054 Johnson, S. B., Schwarz, B., Bohrsen, E., Cogdill, A. P., Bosio, C. M., Wargo, J. A., Lee,
1055 M. P., & Goldszmid, R. S. (2021). Microbiota triggers STING-type I IFN-dependent
1056 monocyte reprogramming of the tumor microenvironment. *Cell*, 184(21), 5338–5356.e21.
1057 <https://doi.org/10.1016/j.cell.2021.09.019>
- 1058 109. Alexander, J. L., Wilson, I. D., Teare, J., Marchesi, J. R., Nicholson, J. K., & Kinross, J. M.
1059 (2017). Gut microbiota modulation of chemotherapy efficacy and toxicity. *Nature Reviews.*
1060 *Gastroenterology & Hepatology*, 14(6), 356–365. <https://doi.org/10.1038/nrgastro.2017.20>
- 1061 110. Daisley, B. A., Chanyi, R. M., Abdur-Rashid, K., Al, K. F., Gibbons, S., Chmiel, J. A.,
1062 Wilcox, H., Reid, G., Anderson, A., Dewar, M., Nair, S. M., Chin, J., & Burton, J. P. (2020).
1063 Abiraterone acetate preferentially enriches for the gut commensal Akkermansia muciniphila
1064 in castrate-resistant prostate cancer patients. *Nature Communications*, 11(1), 4822.
1065 <https://doi.org/10.1038/s41467-020-18649-5>
- 1066 111. Kwa, M., Plottel, C. S., Blaser, M. J., & Adams, S. (2016). The Intestinal Microbiome and
1067 Estrogen Receptor-Positive Female Breast Cancer. *Journal of the National Cancer*
1068 *Institute*, 108(8). <https://doi.org/10.1093/jnci/djw029>
- 1069 112. Komorowski, A. S., & Pezo, R. C. (2020). Untapped “-omics”: the microbial metagenome,
1070 estrobolome, and their influence on the development of breast cancer and response to
1071 treatment. *Breast Cancer Research and Treatment*, 179(2), 287–300.
1072 <https://doi.org/10.1007/s10549-019-05472-w>
- 1073 113. Eisenhofer, R., Minich, J. J., Marotz, C., Cooper, A., Knight, R., & Weyrich, L. S. (2019).
1074 Contamination in Low Microbial Biomass Microbiome Studies: Issues and

- 1075 Recommendations. *Trends in Microbiology*, 27(2), 105–117.
1076 <https://doi.org/10.1016/j.tim.2018.11.003>
- 1077 114. Salter, S. J., Cox, M. J., Turek, E. M., Calus, S. T., Cookson, W. O., Moffatt, M. F., Turner,
1078 P., Parkhill, J., Loman, N. J., & Walker, A. W. (2014). Reagent and laboratory
1079 contamination can critically impact sequence-based microbiome analyses. *BMC Biology*,
1080 12(1), 87. <https://doi.org/10.1186/s12915-014-0087-z>
- 1081 115. Sinha, R., Abu-Ali, G., Vogtmann, E., Fodor, A. A., Ren, B., Amir, A., Schwager, E.,
1082 Crabtree, J., Ma, S., Microbiome Quality Control Project Consortium, Abnet, C. C., Knight,
1083 R., White, O., & Huttenhower, C. (2017). Assessment of variation in microbial community
1084 amplicon sequencing by the Microbiome Quality Control (MBQC) project consortium.
1085 *Nature Biotechnology*, 35(11), 1077–1086. <https://doi.org/10.1038/nbt.3981>
- 1086 116. Morton, J. T., Marotz, C., Washburne, A., Silverman, J., Zaramela, L. S., Edlund, A.,
1087 Zengler, K., & Knight, R. (2019). Establishing microbial composition measurement
1088 standards with reference frames. *Nature Communications*, 10(1), 2719.
1089 <https://doi.org/10.1038/s41467-019-10656-5>
- 1090 117. Lin, H., & Peddada, S. D. (2020). Analysis of compositions of microbiomes with bias
1091 correction. *Nature Communications*, 11(1), 3514. [https://doi.org/10.1038/s41467-020-](https://doi.org/10.1038/s41467-020-17041-7)
1092 [17041-7](https://doi.org/10.1038/s41467-020-17041-7)
- 1093 118. Lin, H., & Peddada, S. D. (2020). Analysis of microbial compositions: a review of
1094 normalization and differential abundance analysis. *NPJ Biofilms and Microbiomes*, 6(1), 60.
1095 <https://doi.org/10.1038/s41522-020-00160-w>
- 1096 119. Yatsunenkov, T., Rey, F. E., Manary, M. J., Trehan, I., Dominguez-Bello, M. G., Contreras,
1097 M., Magris, M., Hidalgo, G., Baldassano, R. N., Anokhin, A. P., Heath, A. C., Warner, B.,
1098 Reeder, J., Kuczynski, J., Caporaso, J. G., Lozupone, C. A., Lauber, C., Clemente, J. C.,
1099 Knights, D., ... Gordon, J. I. (2012). Human gut microbiome viewed across age and
1100 geography. *Nature*, 486(7402), 222–227. <https://doi.org/10.1038/nature11053>

- 1101 120. He, Y., Wu, W., Zheng, H.-M., Li, P., McDonald, D., Sheng, H.-F., Chen, M.-X., Chen, Z.-
1102 H., Ji, G.-Y., Zheng, Z.-D.-X., Mujagond, P., Chen, X.-J., Rong, Z.-H., Chen, P., Lyu, L.-Y.,
1103 Wang, X., Wu, C.-B., Yu, N., Xu, Y.-J., ... Zhou, H.-W. (2018). Regional variation limits
1104 applications of healthy gut microbiome reference ranges and disease models. *Nature*
1105 *Medicine*, 24(10), 1532–1535. <https://doi.org/10.1038/s41591-018-0164-x>
- 1106 121. Deschasaux, M., Bouter, K. E., Prodan, A., Levin, E., Groen, A. K., Herrema, H., Tremaroli,
1107 V., Bakker, G. J., Attaye, I., Pinto-Sietsma, S.-J., van Raalte, D. H., Snijder, M. B.,
1108 Nicolaou, M., Peters, R., Zwinderman, A. H., Bäckhed, F., & Nieuwdorp, M. (2018).
1109 Depicting the composition of gut microbiota in a population with varied ethnic origins but
1110 shared geography. *Nature Medicine*, 24(10), 1526–1531. [https://doi.org/10.1038/s41591-](https://doi.org/10.1038/s41591-018-0160-1)
1111 [018-0160-1](https://doi.org/10.1038/s41591-018-0160-1)
- 1112 122. Wirbel, J., Pyl, P. T., Kartal, E., Zych, K., Kashani, A., Milanese, A., Fleck, J. S., Voigt, A.
1113 Y., Palleja, A., Ponnudurai, R., Sunagawa, S., Coelho, L. P., Schrotz-King, P., Vogtmann,
1114 E., Habermann, N., Niméus, E., Thomas, A. M., Manghi, P., Gandini, S., ... Zeller, G.
1115 (2019). Meta-analysis of fecal metagenomes reveals global microbial signatures that are
1116 specific for colorectal cancer. *Nature Medicine*, 25(4), 679–689.
1117 <https://doi.org/10.1038/s41591-019-0406-6>
- 1118 123. Thomas, A. M., Manghi, P., Asnicar, F., Pasolli, E., Armanini, F., Zolfo, M., Beghini, F.,
1119 Manara, S., Karcher, N., Pozzi, C., Gandini, S., Serrano, D., Tarallo, S., Francavilla, A.,
1120 Gallo, G., Trompetto, M., Ferrero, G., Mizutani, S., Shiroma, H., ... Segata, N. (2019).
1121 Metagenomic analysis of colorectal cancer datasets identifies cross-cohort microbial
1122 diagnostic signatures and a link with choline degradation. *Nature Medicine*, 25(4), 667–678.
1123 <https://doi.org/10.1038/s41591-019-0405-7>
- 1124 124. Nowell, P. C. (1976). The clonal evolution of tumor cell populations. *Science*, 194(4260),
1125 23–28. <https://doi.org/10.1126/science.959840>
- 1126 125. Greaves, M., & Maley, C. C. (2012). Clonal evolution in cancer. *Nature*.

- 1127 <https://www.nature.com/articles/nature10762>
- 1128 126. Mazor, T., Pankov, A., Johnson, B. E., Hong, C., Hamilton, E. G., Bell, R. J. A., Smirnov, I.
1129 V., Reis, G. F., Phillips, J. J., Barnes, M. J., Idbaih, A., Alentorn, A., Kloezeman, J. J.,
1130 Lamfers, M. L. M., Bollen, A. W., Taylor, B. S., Molinaro, A. M., Olshen, A. B., Chang, S.
1131 M., ... Costello, J. F. (2015). DNA Methylation and Somatic Mutations Converge on the Cell
1132 Cycle and Define Similar Evolutionary Histories in Brain Tumors. *Cancer Cell*, 28(3), 307–
1133 317. <https://doi.org/10.1016/j.ccell.2015.07.012>
- 1134 127. Li, S., Garrett-Bakelman, F. E., Chung, S. S., Sanders, M. A., Hricik, T., Rapaport, F.,
1135 Patel, J., Dillon, R., Vijay, P., Brown, A. L., Perl, A. E., Cannon, J., Bullinger, L., Luger, S.,
1136 Becker, M., Lewis, I. D., To, L. B., Delwel, R., Löwenberg, B., ... Mason, C. E. (2016).
1137 Distinct evolution and dynamics of epigenetic and genetic heterogeneity in acute myeloid
1138 leukemia. *Nature Medicine*, 22(7), 792–799. <https://doi.org/10.1038/nm.4125>
- 1139 128. Vaz, M., Hwang, S. Y., Kagiampakis, I., Phallen, J., Patil, A., O'Hagan, H. M., Murphy, L.,
1140 Zahnow, C. A., Gabrielson, E., Velculescu, V. E., Easwaran, H. P., & Baylin, S. B. (2017).
1141 Chronic Cigarette Smoke-Induced Epigenomic Changes Precede Sensitization of Bronchial
1142 Epithelial Cells to Single-Step Transformation by KRAS Mutations. *Cancer Cell*, 32(3), 360–
1143 376.e6. <https://doi.org/10.1016/j.ccell.2017.08.006>
- 1144 129. Nam, A. S., Chaligne, R., & Landau, D. A. (2021). Integrating genetic and non-genetic
1145 determinants of cancer evolution by single-cell multi-omics. *Nature Reviews. Genetics*,
1146 22(1), 3–18. <https://doi.org/10.1038/s41576-020-0265-5>
- 1147 130. Gutierrez, C., Al'Khafaji, A. M., Brenner, E., Johnson, K. E., Gohil, S. H., Lin, Z.,
1148 Knisbacher, B. A., Durrett, R. E., Li, S., Parvin, S., Biran, A., Zhang, W., Rassenti, L.,
1149 Kipps, T. J., Livak, K. J., Neuberg, D., Letai, A., Getz, G., Wu, C. J., & Brock, A. (2021).
1150 Multifunctional barcoding with ClonMapper enables high-resolution study of clonal
1151 dynamics during tumor evolution and treatment. *Nature Cancer*, 2(7), 758–772.
1152 <https://doi.org/10.1038/s43018-021-00222-8>

- 1153 131. Pleguezuelos-Manzano, C., Puschhof, J., Rosendahl Huber, A., van Hoeck, A., Wood, H.
1154 M., Nomburg, J., Gurjao, C., Manders, F., Dalmaso, G., Stege, P. B., Paganelli, F. L.,
1155 Geurts, M. H., Beumer, J., Mizutani, T., Miao, Y., van der Linden, R., van der Elst, S.,
1156 Genomics England Research Consortium, Garcia, K. C., ... Clevers, H. (2020). Mutational
1157 signature in colorectal cancer caused by genotoxic pks *E. coli*. *Nature*, *580*(7802), 269–
1158 273. <https://doi.org/10.1038/s41586-020-2080-8>
- 1159 132. Yu, T., Guo, F., Yu, Y., Sun, T., Ma, D., Han, J., Qian, Y., Kryczek, I., Sun, D., Nagarsheth,
1160 N., Chen, Y., Chen, H., Hong, J., Zou, W., & Fang, J.-Y. (2017). *Fusobacterium nucleatum*
1161 Promotes Chemoresistance to Colorectal Cancer by Modulating Autophagy. *Cell*, *170*(3),
1162 548–563.e16. <https://doi.org/10.1016/j.cell.2017.07.008>
- 1163 133. Garrett, W. S. (2015). Cancer and the microbiota. *Science*, *348*(6230), 80–86.
1164 <https://doi.org/10.1126/science.aaa4972>
- 1165 134. Ma, C., Han, M., Heinrich, B., Fu, Q., Zhang, Q., Sandhu, M., Agdashian, D., Terabe, M.,
1166 Berzofsky, J. A., Fako, V., Ritz, T., Longerich, T., Theriot, C. M., McCulloch, J. A., Roy, S.,
1167 Yuan, W., Thovarai, V., Sen, S. K., Ruchirawat, M., ... Greten, T. F. (2018). Gut
1168 microbiome-mediated bile acid metabolism regulates liver cancer via NKT cells. *Science*,
1169 *360*(6391). <https://doi.org/10.1126/science.aan5931>
- 1170 135. Goss, G., Tsai, C.-M., Shepherd, F. A., Bazhenova, L., Lee, J. S., Chang, G.-C., Crino, L.,
1171 Satouchi, M., Chu, Q., Hida, T., Han, J.-Y., Juan, O., Dunphy, F., Nishio, M., Kang, J.-H.,
1172 Majem, M., Mann, H., Cantarini, M., Ghorghiu, S., & Mitsudomi, T. (2016). Osimertinib for
1173 pretreated EGFR Thr790Met-positive advanced non-small-cell lung cancer (AURA2): a
1174 multicentre, open-label, single-arm, phase 2 study. *The Lancet Oncology*, *17*(12), 1643–
1175 1652. [https://doi.org/10.1016/S1470-2045\(16\)30508-3](https://doi.org/10.1016/S1470-2045(16)30508-3)
- 1176 136. Thress, K. S., Paweletz, C. P., Felip, E., Cho, B. C., Stetson, D., Dougherty, B., Lai, Z.,
1177 Markovets, A., Vivancos, A., Kuang, Y., Ercan, D., Matthews, S. E., Cantarini, M., Barrett,
1178 J. C., Jänne, P. A., & Oxnard, G. R. (2015). Acquired EGFR C797S mutation mediates

- 1179 resistance to AZD9291 in non–small cell lung cancer harboring EGFR T790M. *Nature*
1180 *Medicine*, 21(6), 560–562. <https://doi.org/10.1038/nm.3854>
- 1181 137. DiNardo, C. D., Stein, E. M., de Botton, S., Roboz, G. J., Altman, J. K., Mims, A. S.,
1182 Swords, R., Collins, R. H., Mannis, G. N., Pollyea, D. A., Donnellan, W., Fathi, A. T.,
1183 Pigneux, A., Erba, H. P., Prince, G. T., Stein, A. S., Uy, G. L., Foran, J. M., Traer, E., ...
1184 Kantarjian, H. M. (2018). Durable Remissions with Ivosidenib in IDH1-Mutated Relapsed or
1185 Refractory AML. *The New England Journal of Medicine*, 378(25), 2386–2398.
1186 <https://doi.org/10.1056/NEJMoa1716984>
- 1187 138. Quek, L., David, M. D., Kennedy, A., Metzner, M., Amatangelo, M., Shih, A., Stoilova, B.,
1188 Quivoron, C., Heiblig, M., Willekens, C., Saada, V., Alsafadi, S., Vijayabaskar, M. S.,
1189 Peniket, A., Bernard, O. A., Agresta, S., Yen, K., MacBeth, K., Stein, E., ... Vyas, P. (2018).
1190 Clonal heterogeneity of acute myeloid leukemia treated with the IDH2 inhibitor enasidenib.
1191 *Nature Medicine*, 24(8), 1167–1177. <https://doi.org/10.1038/s41591-018-0115-6>
- 1192 139. Roboz, G. J., DiNardo, C. D., Stein, E. M., de Botton, S., Mims, A. S., Prince, G. T.,
1193 Altman, J. K., Arellano, M. L., Donnellan, W., Erba, H. P., Mannis, G. N., Pollyea, D. A.,
1194 Stein, A. S., Uy, G. L., Watts, J. M., Fathi, A. T., Kantarjian, H. M., Tallman, M. S., Choe, S.,
1195 ... Stone, R. M. (2020). Ivosidenib induces deep durable remissions in patients with newly
1196 diagnosed IDH1-mutant acute myeloid leukemia. *Blood*, 135(7), 463–471.
1197 <https://doi.org/10.1182/blood.2019002140>
- 1198 140. Merlevede, J., Droin, N., Qin, T., Meldi, K., Yoshida, K., Morabito, M., Chautard, E.,
1199 Auboeuf, D., Fenaux, P., Braun, T., Itzykson, R., de Botton, S., Quesnel, B., Commes, T.,
1200 Jourdan, E., Vainchenker, W., Bernard, O., Pata-Merci, N., Solier, S., ... Solary, E. (2016).
1201 Mutation allele burden remains unchanged in chronic myelomonocytic leukaemia
1202 responding to hypomethylating agents. *Nature Communications*, 7, 10767.
1203 <https://doi.org/10.1038/ncomms10767>
- 1204 141. Turati, V. A., Guerra-Assunção, J. A., Potter, N. E., Gupta, R., Ecker, S., Daneviciute, A.,

- 1205 Tarabichi, M., Webster, A. P., Ding, C., May, G., James, C., Brown, J., Conde, L., Russell,
1206 L. J., Ancliff, P., Inglott, S., Cazzaniga, G., Biondi, A., Hall, G. W., ... Enver, T. (2021).
1207 Chemotherapy induces canalization of cell state in childhood B-cell precursor acute
1208 lymphoblastic leukemia. *Nature Cancer*, 2(8), 835–852. [https://doi.org/10.1038/s43018-](https://doi.org/10.1038/s43018-021-00219-3)
1209 021-00219-3
- 1210 142. Dobson, S. M., García-Prat, L., Vanner, R. J., Wintersinger, J., Waanders, E., Gu, Z.,
1211 McLeod, J., Gan, O. I., Grandal, I., Payne-Turner, D., Edmonson, M. N., Ma, X., Fan, Y.,
1212 Voisin, V., Chan-Seng-Yue, M., Xie, S. Z., Hosseini, M., Abelson, S., Gupta, P., ... Dick, J.
1213 E. (2020). Relapse-Fated Latent Diagnosis Subclones in Acute B Lineage Leukemia Are
1214 Drug Tolerant and Possess Distinct Metabolic Programs. *Cancer Discovery*, 10(4), 568–
1215 587. <https://doi.org/10.1158/2159-8290.CD-19-1059>
- 1216 143. Marine, J.-C., Dawson, S.-J., & Dawson, M. A. (2020). Non-genetic mechanisms of
1217 therapeutic resistance in cancer. *Nature Reviews. Cancer*, 20(12), 743–756.
1218 <https://doi.org/10.1038/s41568-020-00302-4>
- 1219 144. Barrett, M., Hand, C. K., Shanahan, F., Murphy, T., & O'Toole, P. W. (2020). Mutagenesis
1220 by Microbe: the Role of the Microbiota in Shaping the Cancer Genome. *Trends in Cancer*
1221 *Research*, 6(4), 277–287. <https://doi.org/10.1016/j.trecan.2020.01.019>
- 1222 145. Gur, C., Ibrahim, Y., Isaacson, B., Yamin, R., Abed, J., Gamliel, M., Enk, J., Bar-On, Y.,
1223 Stanietsky-Kaynan, N., Copenhagen-Glazer, S., Shussman, N., Almogy, G., Cuapio, A.,
1224 Hofer, E., Mevorach, D., Tabib, A., Ortenberg, R., Markel, G., Miklić, K., ... Mandelboim, O.
1225 (2015). Binding of the Fap2 protein of *Fusobacterium nucleatum* to human inhibitory
1226 receptor TIGIT protects tumors from immune cell attack. *Immunity*, 42(2), 344–355.
1227 <https://doi.org/10.1016/j.immuni.2015.01.010>
- 1228 146. Dunn, G. P., Bruce, A. T., Ikeda, H., Old, L. J., & Schreiber, R. D. (2002). Cancer
1229 immunoediting: from immunosurveillance to tumor escape. *Nature Immunology*, 3(11),
1230 991–998. <https://doi.org/10.1038/ni1102-991>

- 1231 147. Jourdain, A., Duchmann, M., Willekens, C., Solary, É., Perié, L., & Laplane, L. (2021).
 1232 Évolution clonale: Qu'est-ce qu'un clone. *La Biologie Au Défi de L'histoire; Chapitre, 10*,
 1233 167–188.
 1234 https://www.cairn.info/load_pdf.php?ID_ARTICLE=EDMAT_LOISC_2021_01_0167&download=1
 1235 oad=1
- 1236 148. Fluckiger, A., Daillère, R., Sassi, M., Sixt, B. S., Liu, P., Loos, F., Richard, C., Rabu, C.,
 1237 Alou, M. T., Goubet, A.-G., Lemaitre, F., Ferrere, G., Derosa, L., Duong, C. P. M.,
 1238 Messaoudene, M., Gagné, A., Joubert, P., De Sordi, L., Debarbieux, L., ... Zitvogel, L.
 1239 (2020). Cross-reactivity between tumor MHC class I–restricted antigens and an
 1240 enterococcal bacteriophage. *Science*.
 1241 <https://science.sciencemag.org/content/369/6506/936.abstract>
- 1242 149. Bessell, C. A., Isser, A., Havel, J. J., Lee, S., Bell, D. R., Hickey, J. W., Chaisawangwong,
 1243 W., Glick Bieler, J., Srivastava, R., Kuo, F., Purohit, T., Zhou, R., Chan, T. A., & Schneck,
 1244 J. P. (2020). Commensal bacteria stimulate antitumor responses via T cell cross-reactivity.
 1245 *JCI Insight*, 5(8). <https://doi.org/10.1172/jci.insight.135597>
- 1246 150. Doolittle, W. F. (1999). Phylogenetic classification and the universal tree. *Science*,
 1247 284(5423), 2124–2129. <https://doi.org/10.1126/science.284.5423.2124>
- 1248 151. Doolittle, W. F., & Baptiste, E. (2007). Pattern pluralism and the Tree of Life hypothesis.
 1249 *Proceedings of the National Academy of Sciences of the United States of America*, 104(7),
 1250 2043–2049. <https://doi.org/10.1073/pnas.0610699104>
- 1251 152. O'Malley, M. A., & Koonin, E. V. (2011). How stands the Tree of Life a century and a half
 1252 after The Origin? *Biology Direct*, 6(1), 32. <https://doi.org/10.1186/1745-6150-6-32>
- 1253 153. Byndloss, M. X., Olsan, E. E., Rivera-Chávez, F., Tiffany, C. R., Cevallos, S. A., Lokken, K.
 1254 L., Torres, T. P., Byndloss, A. J., Faber, F., Gao, Y., Litvak, Y., Lopez, C. A., Xu, G., Napoli,
 1255 E., Giulivi, C., Tsolis, R. M., Revzin, A., Lebrilla, C. B., & Bäumler, A. J. (2017). Microbiota-
 1256 activated PPAR- γ signaling inhibits dysbiotic Enterobacteriaceae expansion. *Science*,

- 1257 357(6351), 570–575. <https://doi.org/10.1126/science.aam9949>
- 1258 154. Butler, D. S. C., Cafaro, C., Putze, J., Wan, M. L. Y., Tran, T. H., Ambite, I., Ahmadi, S.,
1259 Kjellström, S., Welinder, C., Chao, S. M., Dobrindt, U., & Svanborg, C. (2021). A bacterial
1260 protease depletes c-MYC and increases survival in mouse models of bladder and colon
1261 cancer. *Nature Biotechnology*, 39(6), 754–764. <https://doi.org/10.1038/s41587-020-00805-3>
- 1262 155. Kusters, J. G., van Vliet, A. H. M., & Kuipers, E. J. (2006). Pathogenesis of *Helicobacter*
1263 *pylori* infection. *Clinical Microbiology Reviews*, 19(3), 449–490.
1264 <https://doi.org/10.1128/CMR.00054-05>
- 1265 156. Suerbaum, S., & Josenhans, C. (2007). *Helicobacter pylori* evolution and phenotypic
1266 diversification in a changing host. In *Nature Reviews Microbiology* (Vol. 5, Issue 6, pp. 441–
1267 452). <https://doi.org/10.1038/nrmicro1658>
- 1268 157. Anandasabapathy, S., Jhamb, J., Davila, M., Wei, C., Morris, J., & Bresalier, R. (2007).
1269 Clinical and endoscopic factors predict higher pathologic grades of Barrett dysplasia.
1270 *Cancer*, 109(4), 668–674. <https://doi.org/10.1002/cncr.22451>
- 1271 158. Islami, F., & Kamangar, F. (2008). *Helicobacter pylori* and Esophageal Cancer Risk: A
1272 Meta-analysis. In *Cancer Prevention Research* (Vol. 1, Issue 5, pp. 329–338).
1273 <https://doi.org/10.1158/1940-6207.capr-08-0109>
- 1274 159. Petrova, V., Annicchiarico-Petruzzelli, M., Melino, G., & Amelio, I. (2018). The hypoxic
1275 tumour microenvironment. *Oncogenesis*, 7(1), 10. <https://doi.org/10.1038/s41389-017-0011-9>
- 1276 0011-9
- 1277 160. Rundell, E. A., Banta, L. M., Ward, D. V., Watts, C. D., Birren, B., & Esteban, D. J. (2014).
1278 16S rRNA gene survey of microbial communities in Winogradsky columns. *PloS One*, 9(8),
1279 e104134. <https://doi.org/10.1371/journal.pone.0104134>
- 1280 161. Hoshino, T., Doi, H., Uramoto, G.-I., Wörmer, L., Adhikari, R. R., Xiao, N., Morono, Y.,
1281 D'Hondt, S., Hinrichs, K.-U., & Inagaki, F. (2020). Global diversity of microbial communities
1282 in marine sediment. *Proceedings of the National Academy of Sciences of the United States*

- 1283 *of America*, 117(44), 27587–27597. <https://doi.org/10.1073/pnas.1919139117>
- 1284 162. Fenchel, T., & Finlay, B. (2008). Oxygen and the spatial structure of microbial
 1285 communities. *Biological Reviews of the Cambridge Philosophical Society*, 83(4), 553–569.
 1286 <https://doi.org/10.1111/j.1469-185X.2008.00054.x>
- 1287 163. Semenza, G. L. (2008). Tumor metabolism: cancer cells give and take lactate [Review of
 1288 *Tumor metabolism: cancer cells give and take lactate*]. *The Journal of Clinical Investigation*,
 1289 118(12), 3835–3837. <https://doi.org/10.1172/JCI37373>
- 1290 164. Bahram, M., Hildebrand, F., Forslund, S. K., Anderson, J. L., Soudzilovskaia, N. A.,
 1291 Bodegom, P. M., Bengtsson-Palme, J., Anslan, S., Coelho, L. P., Harend, H., Huerta-
 1292 Cepas, J., Medema, M. H., Maltz, M. R., Mundra, S., Olsson, P. A., Pent, M., Pölme, S.,
 1293 Sunagawa, S., Ryberg, M., ... Bork, P. (2018). Structure and function of the global topsoil
 1294 microbiome. *Nature*, 560(7717), 233–237. <https://doi.org/10.1038/s41586-018-0386-6>
- 1295 165. Anderson, A. R. A., Weaver, A. M., Cummings, P. T., & Quaranta, V. (2006). Tumor
 1296 morphology and phenotypic evolution driven by selective pressure from the
 1297 microenvironment. *Cell*, 127(5), 905–915. <https://doi.org/10.1016/j.cell.2006.09.042>
- 1298 166. Damaghi, M., West, J., Robertson-Tessi, M., Xu, L., Ferrall-Fairbanks, M. C., Stewart, P.
 1299 A., Persi, E., Fridley, B. L., Altrock, P. M., Gatenby, R. A., Sims, P. A., Anderson, A. R. A.,
 1300 & Gillies, R. J. (2021). The harsh microenvironment in early breast cancer selects for a
 1301 Warburg phenotype. *Proceedings of the National Academy of Sciences of the United*
 1302 *States of America*, 118(3). <https://doi.org/10.1073/pnas.2011342118>
- 1303 167. Frankenstein, Z., Basanta, D., Franco, O. E., Gao, Y., Javier, R. A., Strand, D. W., Lee, M.,
 1304 Hayward, S. W., Ayala, G., & Anderson, A. R. A. (2020). Stromal reactivity differentially
 1305 drives tumour cell evolution and prostate cancer progression. *Nature Ecology & Evolution*,
 1306 4(6), 870–884. <https://doi.org/10.1038/s41559-020-1157-y>
- 1307 168. Salehi, S., Kabeer, F., Ceglia, N., Andronescu, M., Williams, M. J., Campbell, K. R.,
 1308 Masud, T., Wang, B., Biele, J., Brimhall, J., Gee, D., Lee, H., Ting, J., Zhang, A. W., Tran,

- 1309 H., O'Flanagan, C., Dorri, F., Rusk, N., de Algara, T. R., ... Shah, S. P. (2021). Clonal
1310 fitness inferred from time-series modelling of single-cell cancer genomes. *Nature*,
1311 *595*(7868), 585–590. <https://doi.org/10.1038/s41586-021-03648-3>
- 1312 169. Temko, D., Cheng, Y.-K., Polyak, K., & Michor, F. (2017). Mathematical Modeling Links
1313 Pregnancy-Associated Changes and Breast Cancer Risk. *Cancer Research*, *77*(11), 2800–
1314 2809. <https://doi.org/10.1158/0008-5472.CAN-16-2504>
- 1315 170. Williams, M. J., Werner, B., Heide, T., Curtis, C., Barnes, C. P., Sottoriva, A., & Graham, T.
1316 A. (2018). Quantification of subclonal selection in cancer from bulk sequencing data. *Nature*
1317 *Genetics*, *50*(6), 895–903. <https://doi.org/10.1038/s41588-018-0128-6>
- 1318 171. Avanzini, S., & Antal, T. (2019). Cancer recurrence times from a branching process model.
1319 *PLoS Computational Biology*, *15*(11), e1007423.
1320 <https://doi.org/10.1371/journal.pcbi.1007423>
- 1321 172. Curtius, K., Dewanji, A., Hazelton, W. D., Rubenstein, J. H., & Luebeck, G. E. (2021).
1322 Optimal Timing for Cancer Screening and Adaptive Surveillance Using Mathematical
1323 Modeling. *Cancer Research*, *81*(4), 1123–1134. [https://doi.org/10.1158/0008-5472.CAN-](https://doi.org/10.1158/0008-5472.CAN-20-0335)
1324 [20-0335](https://doi.org/10.1158/0008-5472.CAN-20-0335)
- 1325 173. Schwartz, R., & Schäffer, A. A. (2017). The evolution of tumour phylogenetics: principles
1326 and practice. *Nature Reviews. Genetics*, *18*(4), 213–229.
1327 <https://doi.org/10.1038/nrg.2016.170>
- 1328 174. Robertson-Tessi, M., Gillies, R. J., Gatenby, R. A., & Anderson, A. R. A. (2015). Impact of
1329 metabolic heterogeneity on tumor growth, invasion, and treatment outcomes. *Cancer*
1330 *Research*, *75*(8), 1567–1579. <https://doi.org/10.1158/0008-5472.CAN-14-1428>
- 1331 175. Ghaffarizadeh, A., Heiland, R., Friedman, S. H., Mumenthaler, S. M., & Macklin, P. (2018).
1332 PhysiCell: An open source physics-based cell simulator for 3-D multicellular systems. *PLoS*
1333 *Computational Biology*, *14*(2), e1005991. <https://doi.org/10.1371/journal.pcbi.1005991>
- 1334 176. Beerenwinkel, N., Antal, T., Dingli, D., Traulsen, A., Kinzler, K. W., Velculescu, V. E.,

- 1335 Vogelstein, B., & Nowak, M. A. (2007). Genetic progression and the waiting time to cancer.
1336 *PLoS Computational Biology*, 3(11), e225. <https://doi.org/10.1371/journal.pcbi.0030225>
- 1337 177. Tomasetti, C., Vogelstein, B., & Parmigiani, G. (2013). Half or more of the somatic
1338 mutations in cancers of self-renewing tissues originate prior to tumor initiation. In
1339 *Proceedings of the National Academy of Sciences* (Vol. 110, Issue 6, pp. 1999–2004).
1340 <https://doi.org/10.1073/pnas.1221068110>
- 1341 178. Curtius, K., Hazelton, W. D., Jeon, J., & Georg Luebeck, E. (2015). A Multiscale Model
1342 Evaluates Screening for Neoplasia in Barrett's Esophagus. In *PLOS Computational Biology*
1343 (Vol. 11, Issue 5, p. e1004272). <https://doi.org/10.1371/journal.pcbi.1004272>
- 1344 179. Reiter, J. G., Makohon-Moore, A. P., Gerold, J. M., Bozic, I., Chatterjee, K., Iacobuzio-
1345 Donahue, C. A., Vogelstein, B., & Nowak, M. A. (2017). Reconstructing metastatic seeding
1346 patterns of human cancers. *Nature Communications*, 8, 14114.
1347 <https://doi.org/10.1038/ncomms14114>
- 1348 180. Archetti, M., Ferraro, D. A., & Christofori, G. (2015). Heterogeneity for IGF-II production
1349 maintained by public goods dynamics in neuroendocrine pancreatic cancer. *Proceedings of*
1350 *the National Academy of Sciences of the United States of America*, 112(6), 1833–1838.
1351 <https://doi.org/10.1073/pnas.1414653112>
- 1352 181. Basanta, D., Scott, J. G., Fishman, M. N., Ayala, G., Hayward, S. W., & Anderson, A. R. A.
1353 (2012). Investigating prostate cancer tumour-stroma interactions: clinical and biological
1354 insights from an evolutionary game. *British Journal of Cancer*, 106(1), 174–181.
1355 <https://doi.org/10.1038/bjc.2011.517>
- 1356 182. Nichol, D., Rutter, J., Bryant, C., Hujer, A. M., Lek, S., Adams, M. D., Jeavons, P.,
1357 Anderson, A. R. A., Bonomo, R. A., & Scott, J. G. (2019). Antibiotic collateral sensitivity is
1358 contingent on the repeatability of evolution. *Nature Communications*, 10(1), 334.
1359 <https://doi.org/10.1038/s41467-018-08098-6>
- 1360 183. Kaznatcheev, A., Vander Velde, R., Scott, J. G., & Basanta, D. (2017). Cancer treatment

1361 scheduling and dynamic heterogeneity in social dilemmas of tumour acidity and
1362 vasculature. *British Journal of Cancer*, 116(6), 785–792. <https://doi.org/10.1038/bjc.2017.5>

1363 **ACKNOWLEDGEMENTS**

1364

1365 We thank C. Sepich-Poore for providing critical review and feedback on the manuscript and
1366 figures. Figures were created with BioRender.com. The authors also wish to acknowledge the
1367 patients and their families who have helped contribute towards a better understanding of this field.

1368

1369 **FUNDING SOURCES**

1370

1371 G.D.S.-P. is supported by a fellowship from the US National Institutes of Health, National Cancer
1372 Institute (F30 CA243480). T.P. has received funding from the European Research Council (ERC)
1373 under the European Union’s Horizon 2020 research and innovation programme - grant agreement
1374 n° 637647 – IDEM (P.I.: T. Pradeu). L.L. is funded by the Cancéropôle Île-de-France (n°2021-1-
1375 EMERG-54-CNRS DR 5-1) and her team is supported by the Ligue National contre le Cancer
1376 (P.I.: F. Porteu). R.K. is funded in part by grants from the National Cancer Institute within the
1377 National Institutes of Health (R01 CA255206, U24 CA248454). R.K. and C.G. are funded by
1378 Mapping host-microbe-metabolite interactions in 3D to find diet-derived enhancers of immunity
1379 (NIH 1DP1AT010885); Advancing our Understanding of Cancer and the Human Microbiome with
1380 QIIME 2 (NIH U24CA248454) and NIH Director’s Pioneer Award (NIH DP1AT010885). C.G. and
1381 K.C. are funded by Moores Cancer Center Support Grant NIH (NCI P30 CA023100).

1382

1383 **CONFLICTS OF INTEREST**

1384

1385 G.D.S.-P. and R.K. are inventors on a US patent application (PCT/US2019/059647) submitted by

1386 The Regents of the University of California and licensed by Micronoma; that application covers
1387 methods of diagnosing and treating cancer using microbial biomarkers in blood and cancer
1388 tissues. G.D.S.-P. and R.K. are founders of and report stock interest in Micronoma. G.D.S.-P. has
1389 filed several additional US patent applications on cancer microbiome diagnostics that are owned
1390 by The Regents of the University of California. R.K. additionally is a member of the scientific
1391 advisory board for GenCirq, holds an equity interest in GenCirq, and can receive reimbursements
1392 for expenses up to US \$5,000 per year.